Targeting the Final Step of Blood Coagulation : Structure-Activity-Relationship Studies on the Factor XIIIa Inhibitor Tridegin by Böhm, Miriam
Targeting the Final Step of Blood
Coagulation:
Structure-Activity-Relationship Studies
on the Factor XIIIa Inhibitor Tridegin
D I S S E R T A T I O N
zur Erlangung des Doktorgrades (Dr. rer. nat.)
der
Mathematisch-Naturwissenschaftlichen Fakultät
der
Rheinischen Friedrich-Wilhelms-Universität Bonn
vorgelegt von
Miriam Böhm
aus
Erlabrunn
Bonn, Januar 2015

Angefertigt mit Genehmigung der Mathematisch-Naturwissenschaftlichen Fakultät der
Rheinischen Friedrich-Wilhelms-Universität Bonn
1. Gutachter: Prof. Dr. Diana Imhof
2. Gutachter: Prof. Dr. Michael Gütschow
Tag der Promotion: 02.06.2015
Erscheinungsjahr: 2015

Für Robert

Abstract
The prophylaxis and therapy of thrombotic diseases is one of the major columns supporting
our continuously increasing life expectancy and health. The transglutaminase factor XIIIa
(FXIIIa), which is part of the blood coagulation cascade, therefore is an interesting target for
antithrombotic and thrombolytic treatment with enzyme inhibitors. Additionally, powerful
and specific FXIIIa inhibitors are valuable research tools to elucidate the multiple functions
of FXIIIa in more detail. An example for such a powerful inhibitor of FXIIIa can be found
in nature: Tridegin, a 66mer peptide was first isolated from the salivary gland of the giant
amazon leech Haementeria ghilianii in 1997 and is still one of the most potent and specific
FXIIIa inhibitors described. The aim of this thesis is to gain access to the peptide by different
preparation methods and to characterize in detail the inhibitory mechanism and structure of
this interesting peptide. In the course of this research tridegin was synthesized by solid-phase
peptide synthesis followed by oxidative self folding to form disulfide bonds. Additionally,
recombinant expression of the peptide in Escherichia coli was performed. Functional analysis
by enzyme activity and binding assays revealed that the major inhibitory action is localized in
the C-terminal part of the peptide, whereas the N-terminal part contributes to binding affinity.
The disulfide connectivity of both the synthetic and the recombinant peptide variant was
elucidated by mass spectrometric analysis and showed that three different disulfide-linked
isomers were formed. Subsequently, molecular modeling of all three isomers was performed
and the models were docked to the FXIII-A° structure. In general, this work greatly increases
the understanding of the natural FXIIIa inhibitor tridegin, which provides the scientific
community with a valuable research tool and a potential lead structure for the development
of new FXIIIa inhibitors.
I

Zusammenfassung
Die Prophylaxe und Therapie thrombotischer Erkrankungen ist eine der wichtigsten Säulen,
die unsere stetig steigende Lebenserwartung und Gesundheit trägt. Die Transglutaminase
Faktor XIIIa (FXIIIa), die Teil der Blutgerinnungskaskade ist, ist daher ein interessantes Target
für antithrombotische und thrombolytische Behandlungen mit Enzyminhibitoren. Zudem sind
starke und spezifische FXIIIa-Inhibitoren wertvolle Werkzeuge zur detaillierten Erforschung
der verschiedenen Funktionen von FXIIIa. Ein Beispiel für einen solchen wirkungsvollen
Inhibitor für FXIIIa kann man in der Natur finden: Tridegin, ein 66mer Peptid, wurde 1997
aus der Speicheldrüse des Amazonas-Riesenblutegels Haementeria ghilianii isoliert und ist
noch immer einer der potentesten spezifischen bekannten FXIIIa Inhibitoren. Das Ziel dieser
Arbeit ist es, Zugang zu Tridegin durch verschiedene Herstellungsverfahren zu erhalten und
den inhibitorischen Mechanismus und die Struktur dieses interessanten Peptids im Detail zu
charakterisieren. Im Verlauf dieser Untersuchungen wurde Tridegin durch Festphasenpep-
tidsynthese und anschließende oxidative Selbstfaltung zur Ausbildung der Disulfidbrücken
hergestellt. Die rekombinante Expression des Peptids in Escherichia coli war ebenfalls erfolg-
reich. Funktionelle Analysen mittels Enzym-Aktivitäts-Untersuchungen und Bindungsstudien
zeigten, dass die hauptsächliche inhibitorische Aktivität im C-terminalen Teil des Peptids
lokalisiert ist, wohingegen der N-terminale Teil zur Bindungsaffinität des Inhibitors beiträgt.
Die Disulfidverbrückung sowohl der synthetischen als auch der rekombinanten Peptidva-
riante wurde mit Hilfe von Massenspektrometrie aufgeklärt und es wurde gezeigt, dass
drei verschiedene disulfidverbrückte Isomere gebildet wurden. Anschließend wurde eine
computergestützte Modellierung aller drei Isomere sowie ein Docking der Modelle an FXIII-A°
durchgeführt. Insgesamt erhöht diese Arbeit das Verständnis des natürlichen FXIIIa-Inhibitors
Tridegin, welcher der wissenschaftlichen Gemeinschaft ein wertvolles Forschungswerkzeug
und eine potentielle Leitstruktur für die Entwicklung weiterer FXIIIa-Inhibitoren zur Verfü-
gung stellt.
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1 Introduction
The connection between leeches and medicine has been established so long ago, that it
is hard to tell, when these animals were first applied in therapy. This is stressed by the
fact, that “leech” is derived from the Anglo-Saxon word “laece”, which meant physician.1
Even today, leech therapy continues to play a role, for example, when blood flow needs
to be re-established in reattached limbs.2 When it comes to the molecular mechanisms of
leech therapy, the probably most important parts of the leech are the peptides and proteins
secreted into the leech saliva, with which the leech numbs the pain of the bitten animal and
prevents blood coagulation to occur. The most prominent representative of leech-derived
anticoagulants, a peptide named hirudin after the scientific name for the medicinal leech,
Hirudo medicinalis, was already discovered in the beginning of the 20th century.3 Since then,
hirudin has been investigated in great detail and is now applied in clinical practice as a
thrombin inhibitor.4
A wide variety of similar substances have been identified to date, some of which are fully
characterized, and some of which still need further investigation.5 One example of the latter
group is tridegin, a potent inhibitor of the blood coagulation factor XIIIa. Since its first
isolation from the salivary gland of the giant amazon leech Haementeria ghilianii in 1997,
little has been published concerning structure or inhibitory mechanism of tridegin. Therefore,
this thesis is dedicated to intense studies of tridegin with focus on structural analysis of the
inhibitor, its interaction with factor XIIIa and the relationship between the structural and
functional details.
Tridegin as a well characterized inhibitor might serve as a research tool, a drug or a lead
structure for development of new anticoagulants. And the leeches could prove again that
they can live up to their name.
1

2 Theoretical Background
2.1 Transglutaminases
Transglutaminases (Tgases, EC 2.3.2.13) in general are enzymes that catalyze the formation of
-(γ-glutamyl)lysine isopeptide bonds between an acyl donor and an acyl acceptor substrate.
The reaction proceeds via a covalent enzyme-substrate complex between the active center
cysteine side chain and the acyl donor substrate (Figure 2.1).6,7 While transglutaminases
show a high and isoenzyme-dependent substrate specificity for the acyl donor (usually a
glutamine residue in a peptide or protein chain), specificity for the acyl acceptor is relatively
low.6 Besides lysine side chains in peptides or proteins, small amines or even water are
accepted. Therefore, the enzyme-substrate complex can be resolved by the formation of an
isopeptide bond, but also by incorporation of a low molecular weight amine or by hydrolysis
(thereby turning the glutamine residue into glutamate). If the incorporated small amine has
Figure 2.1: Overview over the reactions catalyzed by transglutaminases: After formation of the covalent
intermediate between the acyl donor and the active site cysteine, three different reactions can follow: a)
the incorporation of a small amine, b) hydrolysis of activated thioester, turning the amide substrate into a
carboxylic acid or c) transamidation resulting in the formation of an isopeptide bond. Modified from Griffin et
al.6
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Table 2.1: Human transglutaminases.
Name Synonym Preferred substrates Physiological functions
Tgase 1 Keratinocyte Tgase Q-x-K/R-φ-x-x-x-W-P9 Assembly of the cornified envelope
Tgase 2 Tissue Tgase Q-x-P-φ10 various
Tgase 3 Epidermal Tgase Y/F/W-Q-S/T-R/K-φ11 Assembly of the cornified envelope
Tgase 4 Prostate Tgase – Mediator of cell-matrix-adhesion
Tgase 6 Neuronal Tgase Q-x-x-φ12 neuronal differentiation/apoptosis
Factor XIIIa Fibrin stabilizing factor Q-x-x-φ-x-W-P10 Blood coagulation, wound healing
a second amino group, such as spermidine or spermine, the resulting product can serve as
an acyl acceptor in the next reaction (secondary cross-link, Figure 2.1).6
There are eight different transglutaminases found in the human genome, which show
strong sequence similarity and belong to the superfamily of papain-like cysteine proteases.6
All members of this family share a common catalytic triad in the active site, consisting of
cysteine, histidine and aspartate or asparagine. However, only six of these transglutaminases
have been described at protein level so far (Table 2.1). Additionally, “erythrocyte-bound
4.2” has been identified as a homologue, but due to a mutation of the active site cysteine
it is no longer enzymatically active and serves structural purposes.6 All transglutaminases
require Ca2+ for their crosslinking function. Additionally, Tgases 2 and 3 can be negatively
regulated by the binding of either GTP or GDP, which is not the case for factor XIIIa or Tgase 1.
However, Tgases 1 and 3 as well as Factor XIIIa can be activated by proteolytic cleavage,
which, in turn, is not described for Tgase 2.8
Of the six transglutaminases in humans, transglutaminase 2 (or tissue transglutaminase)
is probably the best characterized. It is ubiquitously expressed and localized both intra- and
extracellularly.13 Besides its transglutaminase activity, it has been shown to act as a GTPase,
protein disulfide isomerase and kinase. Tgase 2 plays a role in cell death and differentiation,
matrix stabilization, adhesion and migration.6,13 It is also involved in a number of pathogenic
processes, such as celiac disease and cystic fibrosis.14,15
Transglutaminase 1 is expressed predominantly in keratinocytes, where it is anchored to
the keratinocyte plasma membrane via palmitoylation and myristoylation. It helps in the
assembly of the cornified envelope, consisting of heavily cross-linked proteins in the cornified
layer of the skin.16,17 Low levels of Tgase 1 have been shown to be associated with Lamellar
ichthyosis, a rare epidermal disorder that results in extensive scaling of the skin.18 Mice
deficient in Tgase 1 show a phenotype similar to the disease and die shortly after birth due
to an impaired barrier function of the skin.19
Transglutaminase 3 is expressed in the squamous epithelium and is also involved in
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cornification.16,17 Tgase 3 has been described as an auto-antigen, which might be involved
in the pathophysiology of dermatitis herpetiformis.16
Relatively little is known about transglutaminase 4, which is uniquely expressed in the
prostate gland.20 Recently, Tgase 4 has been shown to increase the aggressiveness of prostate
cancer cells by mediating cell-matrix-adhesion.21
Transglutaminase 6 is predominantly expressed in the central nervous system. Its ex-
pression pattern during embryogenesis suggests a role in neuronal differentiation and/or
programmed cell death.22
The biochemistry and physiological role of factor XIIIa will be described in detail in the
following sections.
2.2 Coagulation Factor XIIIa
Factor XIIIa (FXIIIa) was first described in a short article by Laki and Lóránd in 1948 as
a thermolabile component of the blood serum that, in presence of calcium ions, renders
a blood clot insoluble in highly concentrated urea solutions.23 Therefore, FXIIIa is also
called Laki-Lorand-Factor or fibrin-stabilizing factor. Later, in 1964, it was shown that this
fibrin-stabilizing factor was present as a precursor (FXIII) in plasma, and that it needs to be
activated by thrombin.24 Knowledge on FXIII and FXIIIa has increased significantly since
then. As more different forms and activation states of FXIII were found, Muszbek et al.
suggested a nomenclature, which will be used throughout this document.25
2.2.1 Localization and activation of FXIII
FXIII is present in the plasma as an A2B2-heterotetramer. The two A subunits (FXIII-A)
harbor the enzymatic activity, while the B-subunits (FXIII-B) have an inhibitory and carrier
function.26 This tetrameric form is referred to as plasmatic FXIII (pFXIII). Additionally,
FXIII can be found in the cytoplasm of different cell types, mainly in platelets and mono-
cytes/macrophages. In this case, it is present as an A2-dimer.27
The pFXIII (A2B2) circulates in the blood in an average concentration of 21.0µg/ml.28
There is a 50 % excess of the B-subunit over the A-subunit, however, only about 1 % of the
A-subunit are present in free form. A recent re-evaluation of the binding constant between
the two types of FXIII subunits revealed a Kd value in the range of 10
-10 M, which is in good
agreement with the measured proportions of the free subunits in plasma.29 The A-subunit is
synthesized primarily in bone marrow, whereas the B-subunit originates from liver cells.29
From patients deficient in FXIII-B, it is known that the B-subunits protects the catalytic
A-subunit from clearance (see also section 2.3.1). Therefore, a high proportion of complexed
5
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Figure 2.2: Different ways of activation for plasma FXIII. Proteolytic activation is probably the physiological
way of pFXIII activation (A), while activation with calcium ions alone requires unphysiologically high calcium
concentrations (B). Abbreviations as suggested by Muszbek et al. are given below. Modified from Muszbek
et al.25
FXIII-A is crucial to maintain FXIII plasma levels. However, the B-subunit also inhibits the
activation of pFXIII, so that a multi-step activation process is necessary for the formation
of the active enzyme (Figure 2.2). The proposed physiological activation process in plasma
involves the concerted action of both thrombin and calcium ions. First, thrombin cleaves
the activation peptide of FXIII-A (37 amino acids from the N-terminus), then the binding
of calcium ions induces dissociation of the B-subunits and a conformational change in the
A-subunit that uncovers the active center.24,30 The cleavage of the activation peptide is
enhanced in the presence of fibrinogen or non-cross-linked fibrin31 and also the dissociation
of the B-subunit is greatly facilitated in the presence of fibrin.30 Additionally, pFXIII can also
be activated by non-physiological high Ca2+ concentrations (>30 mM). In this case, Ca2+
ions alone are able to induce dissociation of the B-subunits and a subsequent conformational
change in the A-subunits, thereby activating the enzyme (denoted FXIII-A°).30,32 Whether
this mechanism plays any role in the in vivo activation of pFXIII remains questionable.
In contrast, intracellular FXIII (cFXIII) behaves differently. While cFXIII is identical to the
A-subunit of pFXIII, it is not accompanied by B-subunits and activated more readily by Ca2+-
ions alone (Figure 2.3). This activation occurs already at concentrations of 2 mM Ca2+, albeit
very slowly.33 For maintenance of activity, 2 mM Ca2+ were required, at lower concentrations
the enzyme was shown to deactivate again. Both the Ca2+-dependent activation as well as
the deactivation are reversible. Still, these calcium concentrations are much higher than the
6
2.2 Coagulation Factor XIIIa
Figure 2.3: Cellular FXIII is not bound to B-subunits, therefore activation occurs more readily in presence of
calcium ions (A). Proteolytic activation by thrombin or, supposedly, other proteases is nevertheless possible
(B). Modified from Muszbek et al.25
10-4 mM of calcium usually found in resting cells.33 It is suggested that Ca2+-ion influx after
stimulation of cells could activate cFXIII in vivo.34 Additionally, cFXIII can also be activated
by proteolytic cleavage. Activation by thrombin proceeds similar as described for pFXIII,
omitting the B-subunit dissociation. In platelets, activation of cFXIII by the cysteine protease
calpain has been described.35 However, in activated platelets no proteolytic truncation has
been observed, leaving Ca2+-activation as the more likely pathway in vivo.36
2.2.2 Structure of FXIII-A
The crystal structure of cFXIII has been first described by Yee et al. in 1994.37 Since then, it
has been crystallized several times.38–40 As crystallization of the activated FXIIIa was not
successful in the following years, other approaches were used to gain understanding of the
conformational changes that accompany activation of the enzyme. The crystal structure
of the homologous Tgase 241 was used as a scaffold for homology modeling of FXIIIa.42
Also, hydrogen-deuterium-exchange has been used to study the conformational dynamics
of FXIIIa.43,44 Finally, in 2013 a probably active conformation (Ca2+-activated FXIII-A°)
was crystallized with the help of the covalent inhibitor ZED1301.45 A crystal structure of
the B-subunit, the pFXIII (A2B2-tetramer) or the proteolytically activated FXIIIa is still not
available.
In general, the FXIII-A structure consists of four major domains. The activation peptide
(37 N-terminal amino acids) is followed by a β-sandwich domain (38-184), the catalytic
core domain, which is also the largest domain (185-515) and two β-barrel domains (β-
barrel 1: 516–628 and β-barrel 2: 629–731). This overall structure is conserved in Tgase
2 and Tgase 3 as well.41,46 The catalytic triad of FXIIIa is formed by Cys314, His373 and
Asp396 (Figure 2.4). In the inactive state up to one calcium binding site is populated and
the catalytic site is blocked by the β-barrel 1 domain. The side chain hydroxy group of
Tyr560 forms a hydrogen bond with the sulfur of the active site cysteine.37 Upon activation
7
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A
B C
D E
Figure 2.4: A) Overall domain structure of FXIII-A B) Structure of the inactive FXIII-A2. One monomer is
shown in blue, the other monomer is colored according to domain structure.40 C) Structure of FXIII-A°. The
irreversible inhibitor ZED1301 is shown in blue, Ca2+-ions in violet.45 D) and E) show enlarged views of the
active site in FXIII-A and FXIII-A°, respectively. AP: activation peptide.
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to FXIII-A° by calcium binding, two additional calcium binding sites are populated and the
two β-barrel domains move aside to allow access to the active center. The coordination of
the two additional calcium ions is suggested to be the driving force for this rearrangement.45
During this process, a channel for the lysine substrate is opened and an additional catalytic
diad is formed by His342 and Glu401, which is supposed to facilitate the nucleophilic attack
of the lysine substrate.
In contrast, only little is known about the structure of the B-subunit and the A2B2-tetramer.
The FXIII-B sequence shows a highly repetitive structure containing 10 sushi domains and
is similar to fibronectin.47 Electron microscopy and gradient sedimentation experiments
suggest that the B subunit has an asymmetric, elongated shape.48 The tetramer, in contrast,
has a more compact structure, suggesting that the B-subunit is in some way wrapped around
the A-subunit.48 Further investigations showed, that free, recombinant FXIII-B can form
homodimers, a function that could be attributed to the ninth sushi domain by comparison
with truncated variants. However, the formation of tetrameric complexes with FXIII-A
was dependent on the presence of the first (N-terminal) sushi domain, which is therefore
thought to be responsible for the binding to FXIII-A. The formation of the A2B2-tetramer was
independent on the ability of the truncated variants to form dimers.47
2.2.3 Substrate specificity of FXIIIa
Transglutaminases in general show a relatively high substrate specificity for the glutamine
containing substrate, whereas specificity for the lysine containing substrate is rather low, so
that not only peptides containing lysine residues are accepted, but also small primary amines
like glycine ethyl ester.49 Despite the specificity of FXIIIa for certain glutamine substrates,
it proved difficult to derive a universal consensus sequence. Sugimura et al. determined a
consensus sequence by applying a phage-display library approach. They came up with a
preference for substrates containing a QxxφxWP motif (φ is any hydrophobic amino acid).10
The development of an inhibitor based on this consensus sequence validates this approach.45
Therefore it is even more surprising, that most of the natural substrates of FXIIIa do not
share this common sequence (Table 2.2).50 This indicates that the overall structure of the
substrate might also play an important role.
A recent study using a proteomics approach identified 147 substrates of FXIIIa in blood,
and 48 proteins that were actually incorporated in the plasma clot. Again, a consensus
sequence could not be derived from the data, apart from the complete absence of proline
in the first position C-terminal of the glutamine residue. However, they found an over-
representation of reactive glutamine residues in loop regions after categorizing their hits
according to secondary structure.51 A list of selected FXIIIa substrates is given in Table 2.2.
Further FXIIIa substrates can be found in the transdab database.52
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Table 2.2: Selected glutamine containing substrates of FXIIIa. Updated from Böhm, 2010.53
Sequence Origin Ref.
Natural substrates
...WNSGSSGTGSTGN Q328 NPGSPRPGSTGTW... Fibrinogen α-chain 54
...HWTSESSUSGSTG Q366 WHSESGSFRPDSP... Fibrinogen α-chain 54
...IIPFNRLTIGEGQ Q398 HHLGGAKQAGDV-OH Fibrinogen γ-chain 54
H-EA Q3 QIVQPQSPLTVSQ... Fibronectin 54
...SKIRKPKMCPQLQ Q670 YEMHGPEGLRVGF... α2-Macroglobulin
54
H-N Q2 EQVSPLTLLKLGN... α2-Antiplasmin
55
H-FQSG Q5 VLAALPRTSRQVQ... TAFIa 56
...NQIKAYISMHSYS Q292 HIVFPYSYTRSKS... TAFI 56
...MTPENFTSCGFMQ Q83 IQKGSYPDAILQA... plasminogen activator inhibitor 2b 57
...TSDLQAQSKGNPE Q93 TPVLPEEEAPAPE... Vitronectin 54
...TVMFPPQSVLSLS Q167 SKVLPVPEKAVPY... β-Casein 54
...QERCVDGCSCPEG Q313 LLDEGLCVESTEC... von Willebrand factor 58
...PVIPANMDKKYRS Q378 HLDNFSNQIGKHY... coagulation factor V 51,59
Putative natural substratesc
...DKLGEVNTYAGDL Q77 KKLVPFATELHER... Apolipoprotein A-IV 51
...GTAFVIFGIQDGE Q280 RISLPESLKRIPI... Complement C3 51
...EEVDQVTLYSYKV Q78 STITSRMATTMIQ... ITId heavy chain H2 51
...SVVHLGVPLSVGV Q42 LQDVPRGQVVKGS... Complement C4-B 51
...PVVAEFYGSKEDP Q111 TFYYAVAVVKKDS... Serotransferrin 51
...NGDRIDSLLENDR Q168 QTHMLDVMQDHFS... Clusterin 51
...WLLVAVGSACRFL Q64 EQGHRAEATTLHV... Complement C8 γ-chain 51
Artificial substrates
H-LGPG Q5 SKVIG-OH K9-peptide (Berichrom®-substrate) 60
H-N Q2 EQVSPLTLLKLGN-OH derived from α2-Antiplasmin
60
H-N Q2 EQVSPLTLLK-OH derived from α2-Antiplasmin
55
H-D Q2 MMLPWPAVKL-OH Screening 10
H-W Q2 HKIDLRYNGA-OH Screening 10
H-S Q2 HPLPWPVLML-OH Screening 10
H-SVLSLS Q7 SKVLPVPE-NH2 derived from β-Casein
61
aThrombin-activatable fibrinolysis inhibitor. Q2 is also a substrate glutamine. bQ82 and Q86 are also substrate glutamines.
cFrequently, more than one reactive glutamine residue was found. In this case, only the most N-terminal representative is
chosen here. dInter-alpha-trypsin inhibitor.
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2.2.4 Involvement in haemostasis and fibrinolysis
The most important biological function of FXIIIa is its involvement in blood coagulation. It
differs from most of the other coagulation enzymes in that it is not a serine protease, but
a transglutaminase. In the final stages of blood coagulation, thrombin cleaves fibrinogen
to form fibrin and also activates FXIII. The fibrin monomers assemble to a non-covalent
fibrin clot, which is then covalently cross-linked by FXIIIa. This is also the reaction that was
originally observed by Laki et al. when they discovered FXIIIa.23 The covalent crosslinking
of fibrin makes the clot insoluble even at high concentrations of urea, while non-cross-linked
fibrin clots dissolve readily under these conditions. Later, measurements of the viscoelastic
properties of cross-linked and non-cross-linked clots showed a remarkable increase in clot
stiffness after FXIIIa treatment.62,63 This is attributed to the crosslinking of α- and γ-fibrin
chains. The fastest reaction is γ-chain dimerization by the reciprocal cross-linking between
Lys406 on one chain, and Gln398 or Gln399 on another chain. This is then followed by the
slower α-chain cross-linking, in which multiple lysine and glutamine residues are involved
and which results in high molecular weight polymers. It is suggested that the second, slower
reaction, has more influence on clot stiffness.27
The action of FXIIIa on fibrin also renders a clot more resistant to fibrinolysis by plasmin.
Initially it was thought that this also results from fibrin cross-linking. However, it was shown
by Fraser et al. that the resistance of the clot to fibrinolysis is almost solely influenced by
α2-antiplasmin (α2-AP), which is covalently attached to the fibrin chains by FXIIIa.
64 α2-AP
is a natural inhibitor of the fibrinolytic protease plasmin. It is secreted by the liver as Met1-
α2-AP, which is a mediocre substrate for FXIIIa, but antiplasmin cleaving enzyme (APCE),
a protease present in the blood, partially converts Met1-α2-AP to Asn1-α2-AP by removing
12 N-terminal amino acids. Asn1-α2-AP is an excellent substrate of FXIIIa and is rapidly
incorporated into the clot.36 The importance of this physiological process is underlined by the
fact that α2- AP-deficiency leads to severe bleeding tendency very similar to FXIII-deficiency
(see section 2.3.1).65
Another component of the fibrinolytic system that is cross-linked to fibrin by FXIIIa is
plasminogen activator inhibitor 2 (PAI-2).57 This protein is usually found in monocytes, but
can also be secreted and is detectable in plasma during pregnancy.66,67 It is an inhibitor
of urokinase (also called urokinase-type plasminogen activator or u-PA). PAI-2 prevents
urokinase from converting plasminogen to plasmin, and therefore has an antifibrinolytic
function.67
Thrombin-activatable fibrinolysis inhibitor (TAFI) is a more recently described inhibitor of
fibrinolysis, which is also incorporated in the clot by FXIIIa.56 It is activated by thrombin,
most efficiently in the presence of thrombomodulin, resulting in activated TAFI (TAFIa). It
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Figure 2.5: Overview of fibrinolytic and anti-fibrinolytic processes. Substrates of FXIIIa are marked in gray.
then acts by inhibiting a positive feedback mechanism in the activation of plasmin: Plasmin
cleaves fibrin after selected lysine and arginine residues. These free C-terminal lysine residues
enhance the formation of plasmin from plasminogen, thereby increasing fibrinolysis.36,68
TAFIa eliminates these C-terminal lysine and arginine residues from the partially degraded
fibrin and reduces this positive feedback mechanism. The covalent cross-linking of TAFI and
fibrin is suggested to facilitate the activation of TAFI and protect it from degradation.56
The interaction of FXIIIa with platelets and the involvement of the intracellular cFXIII of
platelets in the coagulation process seems to be more complex. Although cFXIII is present
in platelets in huge amounts reaching about 3 % of total cell protein,69 the influence of
cFXIII from platelets on the crosslinking of the clot is negligible and cFXIII is not released
during platelet activation.36,70 The presence of platelets themselves, however – independently
on whether or not they contain cFXIII – did accelerate the fibrin cross-linking reaction of
pFXIIIa, indicating that platelets provide a catalytic surface by a yet unknown mechanism.36
The role of cFXIII inside platelets has also been investigated in more detail. There are
contradictory findings on whether or not cFXIII is involved in clot retraction, i.e. a platelet
mediated shrinking of the clot that pulls the edges of the lesion closer together.36,71,72
Studies on the localization of cFXIII inside the platelets showed a diffuse, cytoplasmatic
distribution of cFXIII in resting platelets, but upon activation of the platelets by either
thrombin or Ca2+-influx, cFXIII rapidly relocalizes to the periphery. As this is a region of
major cytoskeletal reorganization in activated platelets, and as FXIIIa has been shown to
associate with cytoskeletal proteins, an involvement of FXIIIa in cytoskeletal stabilization
was suggested.73
The whole process of fibrinolysis is summarized in Figure 2.5. With these findings in mind,
it is evident that FXIIIa is a key player in the regulation of fibrinolysis and clot stability and
has an overall anti-fibrinolytic effect. However, recently other physiological roles for FXIII
have been suggested, and will be reviewed in the following section.
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2.2.5 Other physiological functions
Multiple physiological functions for FXIIIa have been suggested apart from the involvement in
blood coagulation. This includes a participation in wound healing, angiogenesis, maintenance
of pregnancy, inflammation, immune response, cardiac protection and bone metabolism,
which have recently been reviewed.36,50,74 Figure 2.6 gives an overview on this topic.
Wound healing and angiogenesis An important additional function of FXIIIa is its influence
on wound healing processes. An impaired wound healing has been documented both in
FXIII-A deficient humans and mice.75,76 When the closure of coutaneous wounds was studied
in FXIII-A deficient mice, they showed poor epidermal regeneration, formation of abnormal
scar tissue and necrosis. Only 73 % of total wound closure was reached after 11 days, a time
span sufficient for wound closure in control animals. The substitution of FXIII in the deficient
mice, in contrast, resulted in nearly normal wound healing.76 This suggests that pFXIII is
sufficient to restore the normal phenotype, despite the cFXIII deficiency of the mice, which
was not affected by FXIII substitution.76 The molecular mechanism is not fully understood
yet. The most important physiological processes involved in wound healing are fibrin gel
formation, invasion of macrophages, migration and proliferation of fibroblasts, production
of extracellular matrix and angiogenesis.36 FXIIIa seems to be involved in several steps of
this process. It was shown that FXIIIa (but not inactivated FXIIIa) significantly enhances
proliferation and migration of monocytes and fibroblasts and also reduces apoptosis in these
cell types.77 Additionally, FXIIIa is known to cross-link certain matrix proteins, for example
fibronectin, which is covalently cross-linked by FXIIIa and is also attached to fibrin-clots,
thereby enhancing fibroblast migration into the clot.36,50 Finally, FXIIIa is also pro-angiogenic,
a property not uncommon among coagulation enzymes that is also the case for thrombin,
factor VII and tissue factor.78 Dardik et al. showed that FXIIIa had a positive influence on
migration and proliferation of endothelial cells and inhibited apoptosis. Additionally, FXIIIa
treatment lowered the expression of thrombospondin 1, a well-characterized anti-angiogenic
factor, in these cells. Again, these effects were not seen with inactivated FXIIIa.79 The effect
of FXIIIa on angiogenesis in vivo was also evaluated. In a murine neonatal cardiac allograft
model, a dose dependent increase in blood vessels was found when injected with FXIIIa.80
This angiogenic function of FXIIIa is assumed to play an important role in wound healing.
Maintenance of pregnancy Besides bleeding, premature abortion is a common symptom
in FXIII deficient women. Of 124 reported cases of pregnancies in FXIII deficient patients
without prophylactic therapy, 91 % resulted in miscarriages. When pFXIII is substituted,
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Figure 2.6: Physiological functions of FXIIIa.
pregnancy is largely normal in these patients.81 An interesting finding is the proliferation of
cFXIII containing cells in the placenta in the first trimester of pregnancy.82 However, the fact
that pFXIII substitution is sufficient to maintain pregnancies leads to the conclusion, that
pFXIII is of primary importance.36 It has been shown in case of a deficient patient that the
absence of FXIIIa impaired the formation of the cytotrophoblastic shell, a layer that connects
the fetal and maternal parts of the placenta. It is thought that FXIIIa serves an important
function in the cross-linking of extracellular matrix proteins in this region thereby stabilizing
the placenta.83
Inflammation and immune response The connections between FXIII and infection control
have been reviewed recently.84 Entrapment of bacteria in blood or similar body fluids is an
evolutionary old mechanism of immune systems, which is still a primary line of defense in
animals like the horseshoe crab, whose hemolymph reacts with coagulation after contact
with bacterial endotoxins.84 This mechanism is still conserved in humans, as shown by the
activation of the blood coagulation upon contact with bacteria. Moreover, FXIII may also be
activated in this process and has been shown to efficiently cross-link bacteria into the forming
clot, thereby immobilizing them. This entrapment can also be seen in vivo, a mechanism
that was shown to be impaired in FXIII deficient mice where bacteria were distributed more
widely in the early stages of infection compared to normal mice.85
Besides this very ancestral line of immune defense, there is also a cross talk between FXIIIa,
the complement system and immune cells.34,74 An example for this is mannan-binding lectin-
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associated serine protease-1 (MASP1), a component of the complement system, that has a
similar substrate specificity as thrombin. It was shown to activate FXIII, but more slowly
than thrombin.86 This could be one of the mechanisms also involved in the cross-linking of
bacteria and fibrin clots. Interestingly, a study on potential substrates of FXIIIa identified a
number of other complement proteins as FXIIIa substrates.51
An example for the connection between FXIIIa and immune cells is the already mentioned
pro-proliferative effect of FXIIIa on monocytes.77
Cardiac protection In 2006, Nahrendorf et al. discovered a novel functional impairment in
FXIII deficient mice. They could show that both homozygous and heterozygous FXIII deficient
mice died due to a cardiac rupture a few days after an experimental myocardial infarct was
introduced. They could also demonstrate that FXIII was present within the healing infarct in
wild-type mice.87 This finding was strengthened by a study on the life span of FXIII deficient
mice, which revealed that especially male mice tended to die of heart bleeding.88 Also, a
similar human case has been reported, which underlines the possible clinical relevance of
this topic.89
Various Additionally, other potential physiological functions of FXIII have been described.
Among these are an involvement in bone and cartilage development. FXIII has been found
in hypertrophic, i.e. terminally differentiated, chondrocytes.90 Furthermore, it has been
shown to participate in the differentiation of these chondrocytes and an involvement in
osteoarthritis is discussed.91 FXIII also came up in a genome wide association study on genes
correlated with obesity92 and most recently, FXIII was shown to be a negative regulator of
adipogenesis.93
2.3 Pathophysiology of Factor XIIIa
Despite the ongoing, thorough investigations of the physiological functions of FXIIIa, its
pathophysiology is only partly understood. While the deficiency in FXIII is well studied, the
implications of FXIII levels on other diseases are still a matter of debate.
2.3.1 Factor XIII deficiency
Factor XIII deficiency is a rare bleeding disorder caused by low levels of (functional) FXIII in
the plasma. Clinical symptoms include frequent bleeding events, for example subcutaneous
hematomas, intramuscular and joint hemorrhage, and intracranial hemorrhage.75 The latter
is also the most frequent cause of fatality and disability in FXIII deficient patients.75,94
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Rebleeding of wounds is a common symptom as well. However, due to the multiple functions
of factor XIII in man, bleeding is not the only symptom of a FXIII deficiency. Most notably,
deficient patients suffer from impaired wound healing and scar formation. In women, FXIII
deficiency leads to recurrent pregnancy losses (see also section 2.2.5).81
Factor XIII deficiency can be inherited (congenital) or acquired. Congenital FXIII deficiency
is a very rare, autosomal recessive disease with a prevalence of 1 in 2 or 3 million people.75,95
It can present as either FXIII-A or FXIII-B deficiency, depending on whether the A- or the
B-subunit is affected. FXIII-A deficiency can be further classified into type I or type II. Type
I deficiency is a quantitative defect. The plasma level of FXIII-A is low or not detectable,
usually caused by a mutation in the F13A-gene which leads to a misfolded or truncated
protein. More than 100 mutations have been reported so far.96 On the other hand, FXIII-A
type II deficiencies are caused by a dysfunctional FXIII-A-subunit. Up to now, there is only
one such example, where an amino acid exchange at the thrombin cleavage site renders
the protein resistant to thrombin cleavage and thereby prevents activation of FXIII.75 A
nonfunctional FXIII-B subunit on the other hand results in increased clearance of FXIII-A
from the plasma, thereby also lowering the plasma levels of FXIII. However, the phenotype is
somewhat milder compared to FXIII-A deficiencies, which is probably due to small amounts
of FXIII-A (about 10 % of the normal value) still present in the plasma.75
Acquired FXIII deficiency may have a variety of causes. As known for other coagulation
factors as well, a high consumption of these enzymes for example during major surgery or
inflammatory bowel disease, can lead to a significant decrease in plasma levels.75 On the
other hand, autoantibodies against FXIII (in most cases the A-subunit, rarely the B-subunit96)
have been reported, which can inhibit FXIIIa, prevent the activation of FXIII or the binding
of FXIII to fibrinogen.97 Most commonly these autoantibodies are found in patients suffering
from autoimmune diseases such as systemic lupus erythematosus.98 Treatment is more
difficult in these cases, as substitution of FXIII is often not successful. Therefore, treatment
is usually focused on suppressing the immune response and/or treating the underlying
autoimmune condition.75
2.3.2 Involvement of FXIII in thrombotic diseases
Since FXIII plays an important role in coagulation and haemostasis, it seems stringent to
look for an involvement of the enzyme in thrombotic diseases (Figure 2.7). However, there
is relatively few evidence that elevated levels of FXIII could influence this type of disease.99
For example, two studies on deep vein thrombosis (DVT) and venous thromboembolism
(VTE) did not find a link between FXIII levels and risk of DVT.100,101 However, it was shown
that FXIII is significantly decreased in patients with pulmonary embolism, and the decrease
16
2.3 Pathophysiology of Factor XIIIa
Figure 2.7: Overview over different complica-
tions arising from venous and arterial throm-
bus formation. In case a thrombus forms in
veins, embolization (i.e. breaking free of the
thrombus) can lead to obstruction of smaller
blood vessels in the lung, causing life threat-
ening pulmonary embolism. Thrombi formed
in the arteria may also embolize and can for
example block capillaries in the brain or heart
muscle, also causing potentially fatal obstruc-
tion of these.
was correlated with the pulmonary occlusion rate. This indicates a consumption of FXIII in
the course of the disease and therefore direct contribution of FXIII to the clot formation.102
On the other hand, high FXIII levels have been linked to an increased risk for myocardial
infarction. This correlation is gender specific and applies only to women.103
A lot of attention has been given to the influence of a common polymorphism of FXIIIa
(Val34Leu) on pathological conditions. The frequency of this allele is about 25 % in Cau-
casians, but significantly lower in Africans or Asians.104 The Val34Leu substitution is close to
the thrombin cleavage site in FXIII and has indeed been shown to enhance the activation
rate by thrombin and affect the cross-linked fibrin structure.105 Studies demonstrated that
the risk of DVT is slightly decreased in both homozygous and heterozygous carriers of the
Val34Leu polymorphism.100 However, there seems to be no influence of this polymorphism
on ischemic stroke, as a recent meta-analysis suggests.106
A more indirect influence of FXIII on atherosclerotic diseases has been investigated by
AbdAlla et al. The group could demonstrate that angiotensin 1 receptors (AT1 receptors) in
monocytes can be cross-linked by cFXIII in the presence of calcium ions and angiotensin II. This
leads to dimerization of the AT1 receptors which renders them hyperresponsive. Interestingly,
an increased level of these AT1 receptor dimers was found in patients that already showed
hypertension.107 Therefore it is suggested that activation of intracellular FXIII may be a risk
factor for the development of atherosclerosis.107
2.3.3 FXIIIa and cancer
There is some evidence that FXIIIa is associated with oncogenesis. For example, FXIII-A
has been shown to be present in acute promyelocytic leukemia cells.108 Activity of FXIIIa
in plasma was elevated in patients with non-small cell lung carcinoma.109 A more detailed
analysis on the function of FXIII in tumor metastasis revealed, that the absence of FXIII
impairs the formation of metastases by hematogenous tumor cells. FXIII is suggested to
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enhance the survival of micrometastases by providing a cross-linked fibrin rich matrix that
prevents natural killer cells from entering the metastatic site and eliminating the tumor.110 A
similar effect was described for brain tumors, where fibrin deposition and the presence of
FXIII were described.111 The whole picture of FXIII influence on tumors is not yet understood,
but will probably be addressed in more detail in the future.
2.4 Inhibition of FXIIIa
The aforementioned association of FXIIIa with pathological conditions makes it an interesting
target for inhibitor design. The earliest “inhibitors” described for fibrin cross-linking were in
fact small, primary amines that were incorporated into fibrin clots and thereby prevented
fibrin cross-linking.49
In the 1980’s, Merck Sharp & Dohme developed imidazolium and thiadiazolium derived
transglutaminase inhibitors.112,113 Additionally, some naturally occuring FXIIIa inhibitors
have been identified, among them the antibiotic cerulenin114 as well as alutacenoic acids115
and derivatives116 and the peptide inhibitor tridegin (see section 2.5). Some experiments
have already shown the potential benefit of FXIIIa inhibitors. One of them was conducted
by Shebuski et al. in 1990 and showed an enhanced t-PA induced thrombolysis in a canine
model, when a FXIIIa inhibitor (L722151, see Table 2.3) was applied prior to thrombus
formation.117 Another study nine years later showed a similar result on a pulmonary embolism
model in ferrets.118 The group administered an inhibitory antibody against FXIIIa and could
demonstrate that not only thrombus lysis after t-PA administration was increased after FXIIIa
inhibition, but also the endogenous thrombolysis without addition of t-PA.118 Matlung et al.,
in contrast, could demonstrate that the inhibition of transglutaminase activity (by L682777)
did not influence the early stage development of atherosclerotic lesions in a mouse model.119
While these inhibitors gave valuable insights in in vivo experiments, they suffer from two
shortcomings: First, most of the small molecule inhibitors did not discriminate well between
the tissue transglutaminase Tgase2 and FXIIIa. Second, they showed only a short plasma
half life of 5-10 min.117 Therefore, in the last years inhibitor design concentrated on peptide-
derived inhibitors. One of them, ZED1301, has been successfully applied for co-crystallization
with active FXIII.45 Because of this, specific FXIIIa inhibitors are both, valuable tools for the
investigation of FXIIIa in vitro and in vivo and potential drug candidates.
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Table 2.3: FXIIIa inhibitors. Potency is given as IC50 and/or k2nd (apparent second-order rate constant),
depending on what information was available.
Inhibitor Potency Specificity
Chemical agents
EDTA (depletion of Ca2+-ions)120 – unspecific
iodoacetamide (alkylation of active
site cysteine)121
– unspecific
Competitive substrates
glycine ethyl ester49
–
does not discriminate between
FXIIIa and Tgase2
dansylcadaverine49
–
does not discriminate between
FXIIIa and Tgase2
Small molecule inhibitors
alutacenoic acid B115
IC50=0.61 µM
does not inhibit papain, calpain or
cathepsin, inhibits Tgase2 with
20fold higher IC50
Cerulenin114
IC50<6.2 µM122
has also antibiotic activity
alutacenoic acid derivative116
IC50=0.026 µM
unknown
L722151112,113
IC50<0.5 µM122
k2nd=23000 M
-1s-1
no effect on thrombin, plasmin,
papain,112 but does inhibit
Tgase2123
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Table 2.3: FXIIIa inhibitors (continued). MAP: Michael acceptor pharmacophore, CMK:Chloro methyl ketone.
Inhibitor Potency Specificity
L682777113,124
IC50<0.08 µM124
k2nd=63000 M
-1s-1
no inhibition of papain or calpain, but
apparent second-order rate
constants are in the same range for
FXIIIa and Tgase2113
Peptide derived inhibitors
ZED1251125
(Ac-Asn-MAP-Glu-Gln-Val-Ser-Pro-
Leu-Thr-Leu-Leu-Lys(alloc)-OH)
k2nd=5500 M
-1s-1 unknown
ZED130145 (Ac-Asp-MAP-Nle-Nle-
Leu-Pro-Trp-Pro-OH)
IC50≈100 nM126
k2nd=4600 M
-1s-1 127
IC50 for Tgase2 about 3000 nM, i.e.
30-fold lower inhibition.126
Cbz-Phe-Glu(CMK)-Val-Lys-Val-Ile-
Gly-NH2
128 k2nd=681 M
-1s-1 unknown
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2.5 Tridegin
The natural FXIIIa inhibitor tridegin was first described in 1997 by Finney et al.129 It was
shown that the salivary gland extract of the giant amazon leech Haementeria ghilianii could
inhibit FXIIIa and subsequently a peptide of approx. 7.3 kDa was isolated. With the help
of an ammonia-release assay, the group determined an IC50 value of about 10 nM and was
furthermore able to derive the 66 amino acid peptide sequence by Edman sequencing, with
few ambiguities. These include the insufficient separation of (carbamidomethylated) cysteine
from glutamate and three positions that could not be determined at all and are suggested to be
post-translationally modified (Figure 2.8A). While the group could directly show that tridegin
inhibited the fibrin cross-linking, an effect of tridegin on other components of the coagulation
cascade (thrombin, factor Xa) or cysteine proteases (bromelain, papain, cathepsin C) was
not detectable. However, tridegin did inhibit Tgase 2, albeit with an IC50 value of about
23-fold the value which was found for FXIIIa. Tridegin is therefore a highly specific and
highly active FXIIIa inhibitor. It is also the first and up to now only natural peptidic FXIIIa
inhibitor described.129
2.5.1 Sequence and homology
Between 2000 and 2002 two patent applications on tridegin were filed130,131 and one more
containing the tridegin sequence as an example for glucose dehydrogenase fusion proteins.132
Two of these patents describe the recombinant expression of tridegin and contain a full
tridegin sequence (no ambiguities) with two additional amino acids (N-terminal methionine
and C-terminal glutamate).131,132 However, no details are given on how this sequence was
derived.
A first clear homologue of tridegin was found by an expressed sequence tag (EST) sequenc-
ing approach of the salivary complexes of Haementeria depressa.133 An alignment of this
sequence with the originally published peptide sequence performed by T. Kühl resulted in
almost the same sequence as published in the patents (see Figure 2.8).134 The H. depressa
gene product of the homologous sequence has not been isolated. Salivary gland extracts
from the H. depressa leech, however, show a significant inhibition of FXIIIa. This is also
true for the related species Haementeria officinalis, suggesting that compounds similar to
tridegin can be found in various species of the Haementeria genus.130 Since there is not
much sequence information on leeches available, clear homologues in more distantly related
species have not been found. Some homology can be assumed to sequence stretches from
the leech Helobdella robusta (of which the whole genome has been sequenced) and the
well-characterized thrombin inhibitor hirudin from the medicinal leech Hirudo medicinalis.
The latter is especially similar to tridegin concerning the spacing of cysteine residues and
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A) Tridegin sequences
KLLPCKEXHQ GIPNPRCXCG ADLEXAQDQY CAFIPQC/ERPR SELIKPMDDI YQRPVC/EFPNL PLKPRC/E 129
MKLLPCKEWHQ GIPNPRCWCG ADLECAQDQY CAFIPQ C RPR SELIKPMDDI YQRPV E FPNL PLKPR E E 131
KLLPCKEWHQ GIPNPRCWCG ADLECAQDQY CAFIPQ C RPR SELIKPMDDI YQRPV E FPNL PLKPR E 134
B) putative homologues
KLLPCKEWHQGIPNPRCWCGADLECAQDQYCAFIPQCRPRSELIKPMDDIYQRPVEFPNLPLKPRE Tridegin
|||||||||||:||||||||||||||||||||||||||||||||||.|||||||:|||.||.||
FSLVASKLLPCKEWHQGVPNPRCWCGADLECAQDQYCAFIPQCRPRSELIKPEDDIYQRPLEFPKLPPKP H. depressa EST
-KLLPCKEWHQGIPNPRCWCGADLECAQDQYCAF-----IPQCRPRSELIKPMD----DIYQRPVEFPNLPLKPRE Tridegin
....|.|..|.: |.|.....|.|...|.. ..||.......||.. |..:.|.|:..
VVYTDCTESGQNL----CLCEGSNVCGQGNKCILGSDGEKNQCVTGEGTPKPQSHNDGDFEEIPEEYLQ------- Hirudin
KLLPCKEWHQGIPNPRCWCGADLECAQDQYCAF------IPQCRPRSELIKPM----------------DDIYQRPVE Tridegin
|||.|.|.|:..|..:||||:.| |:...|||. .|.||||||.::.. ||..|||:.
KLLECTEDHERNPLAKCWCGSVL-CSDGNYCAIPSQVSEEPSCRPRSEYVERNLPGGTRRPRTTPRGICDDTVQRPIS partial mRNA
from H. robusta
Figure 2.8: A) Published sequences of tridegin: Original paper from Finney et al.129 (top), patent from Giersiefen et al.131 (middle) and the sequence derived
by Kühl134 from alignment with the H. depressa EST. B) Alignment of Tridegin with different (putative) homologues: an expressed sequence tag from the H.
depressa,133 Hirudin from H. medicinalis and a partial mRNA sequence from H. robusta.136
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therefore might show structural homology to tridegin (see Figure 2.8). However, the over-
all identity (19.7 %) and similarity (23.7 %) are relatively low, therefore it cannot be said
whether the sequences are truly homologous (“twilight zone”135). Alignment with two
other leech-derived peptides, ornatin from Placobdella ornata and decorsin from Macrobdella
decora yields similar results. Therefore, using structural information from hirudin, ornatin or
decorsin to derive the tridegin structure (i.e the three dimensional fold or the disulfide bond
network) is not a reliable way and other means of structure determination need to be used
(see also section 5.5.1).
2.5.2 Potency
The activity of FXIIIa and thereby also the potency of FXIIIa inhibitors is conveniently mea-
sured in vitro by different assays. The earliest assays available were an amine-incorporation
assay137 as well as different ammonia-release assays.138,139 Later on, the isopeptidase activity
of FXIIIa was exploited to measure activity by the use of fluorogenic or chromogenic assays.
In this case, release of a chromophore, fluorophore or quencher coupled to the glutamine
residue of a FXIIIa substrate is monitored.128,140,141
The potency determined for native (i. e. leech isolated) tridegin determined by Finney et al.
with an ammonia-release assay was given as an IC50 value of approx. 9.2 nM.
129 They also
noted that this IC50 value varied with the concentration of FXIIIa in the assay and suggested
a 1:1 stoichiometry of tridegin and FXIIIa.129
Since then, several other preparations of tridegin have been analyzed, but none of them
from the original organism. Early investigations on tridegin produced recombinantly in E. coli
showed IC50 values of 2-4µM,
131 optimization of the expression procedure (most notably
periplasmic instead of cytoplasmic expression) resulted in an IC50 of 20-40 nM.
142 Analysis of
the same substance with an isopeptidase assay141 resulted in IC50 values of 92-200 nM.
134,143
Tridegin synthesized by solid-phase peptide synthesis and subsequent oxidation yielded an
IC50 of 300-600 nM.
53,134,143
The exact reason for these deviations is not clear. They may partly be due to different
preparation strategies, resulting in different post-translational modifications (in case of the
native tridegin) or different disulfide bonds. Furthermore, the assay conditions may play a
role as well as the method of concentration determination (Bradford assay vs. amino acid
analysis). It is of interest that the values published for the leech-extracted tridegin have never
been reached with any preparation since then, but without access to the native material, it is
impossible to determine whether structural or methodological reasons apply.
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2.5.3 Mutational studies
In one of the patents, Giersiefen et al. started to investigate which part of the tridegin
sequence was most important for inhibitor function. Therefore, they split the sequence
into 25 overlapping 20mer peptides and assayed the inhibitor potency of these relative to
full-length tridegin (Figure 2.9A). The experiment revealed that the main inhibitory activity
resides in the C-terminal part of the peptide.131 They then concentrated on the most potent
20mer found and sequentially exchanged every amino acid to alanine (alanine scanning,
Figure 2.9B) which resulted in a number of candidate amino acids with major influence on
the inhibitor function.
Based on this data, R. Coch continued with the synthesis of longer variants containing
an I50A mutation. Both a full-length variant and a C-terminal 30mer with the mutation
A
B
Figure 2.9: Early truncation and mutation studies on tridegin by Giersiefen et al.131 A) A series of 20mer
peptides from tridegin localizes the major inhibitory function in the C-terminal part of tridegin. B) Alanine
scanning in the most potent 20mer pinpoints influential positions. Concentration of peptides ≈7.3 µM.
Modified from Giersiefen et al.53,131
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Table 2.4: Effect of mutations in the sequence of tridegin or a truncated analogue on inhibitor potency53,143
Peptide No. of amino acids Mutation IC50 [µM]
Tridegin 66 none 0.48
Tridegin 66 I50A 1.12
C37-E66 30 none 1.71
C37-E66 30 I50A 13.8
C37-E66 30 I50A, L62A 68.0
showed strongly decreased inhibitor potency, confirming the importance of the I50 position
fo inhibitor function.143 A later analysis of a 30mer with an additional L62A mutation, a
position also suggested to be important by Giersiefen et al., confirmed the expected decrease
in potency (Table 2.4).53
2.6 Structural Classification of Disulfide Bonds
Disulfide bonds, i.e. the oxidative covalent linkage between two cysteine sulfur atoms, are a
major structural feature in proteins and peptides. About 40 % of all mammalian proteins
contain disulfide bonds, the vast majority of these proteins are localized extracellularly.144,145
Mostly, these disulfide bonds serve structural purposes, as they protect the protein structure
in the (sometimes harsh) extracellular environment. However, in some cases these disulfides
are catalytically active, as for example in thiol-disulfide oxidoreductases. More recently it
has become evident that also allosteric influences of disulfide formation or reduction on
protein function plays a regulatory role.145,146
A classification of the three dimensional conformation of disulfide bonds on the basis of
their bond angles has first been introduced by Richardson in 1981147 and has since been
refined.145 A basic classification can be done on the orientation of the χ2, χ3 and χ
′
2 bond
angles (Figure 2.10). The disulfide bonds are characterized as being either right- or left-
handed depending on whether χ3 is positive or negative, respectively. Furthermore, if χ2,
χ3 and χ
′
2 all have the same orientation (either positive or negative) the disulfide bond is
referred to as a “spiral”, while “hook” refers to a bond where only one of the angles χ2 and
χ ′2 share the same orientation with the χ3 angle. Finally, a disulfide bond where both χ2 and
χ ′2 have the opposite orientation compared to χ3 are referred to as “staples”.145,147 These
are then abbreviated as either right hand (RH) or left hand (LH) spirals, hooks or staples.
For example a right hand spiral is denoted RHSpiral. With this classification, six different
disulfide bonds are possible (the disulfides are treated as symmetrical, i.e. there is only one
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Figure 2.10: There are five χ-angles of the disulfide bond. When only the orientation of these angles is
taken into account (i.e. − or +) and the disulfide bond is treated as symmetrical, 20 different conformations
arise. Modified from Schmidt et al.145
RHHook, independent on which of the two χ2 angles is positive).
For a more detailed classification, the orientation of χ1 and χ
′
1 angles was added. In this
case, a plus or minus sign indicates whether both angles are positive or negative, respectively.
A −/+ oder +/− indicate that χ1 and χ ′1 have different orientations. Thus, −RHStaple would
indicate a minus right handed staple, i.e. the angles for χ1, χ2, χ3, χ
′
2 and χ
′
1 are −, −,
+, − and −. Note that there is only one possibility to form a +/−RHStaple, but there are
both +/−RHHook and −/+RHHook possible. According to this, there are 20 disulfide bond
configurations possible, all of which have been shown to exist in proteins.145 However, not all
showed the same prevalence. The −LHSpiral is the most prevalent in disulfide containing X-
ray structures (24.7 %) and also has the lowest dihedral strain energy. It is therefore assumed
to be the primary structural disulfide.145 In contrast, +RHHook, +RHStaple and +LHStaple
showed a prevalence of <1 % in the same dataset. The conformation of disulfide bonds is
also closely linked to function: while almost all catalytic disulfides are +/−RHHooks, most
allosteric disulfides are −RHStaples.145 When comparing the results from X-ray structures
with NMR structures of the same protein, it became obvious that these are not tightly fixed
conformations. Different NMR structures often showed different conformations. However, in
most cases, the conformation found in X-ray structures could also be confirmed in one of the
NMR structures.148
In general, although there is a lot of information available on the conformation of the
peptide backbone, disulfide conformation is still not very well characterized. This is a problem
especially for multiply bridged, disulfide-rich peptides, because in these the contribution of
the disulfide bonds to the overall structure is extraordinarily large.
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3 Aims of this work
This work aims at a comprehensive understanding of the natural FXIIIa inhibitor tridegin and
its interaction with FXIIIa on a molecular level. Both structural and functional aspects of the
enzyme-inhibitor interaction should be investigated in detail, to deepen our understanding of
the biochemistry of FXIIIa and to provide the scientific community with a well characterized
tool for studying the multiple functions of FXIIIa in vitro and in vivo.
To achieve this, the functional characterizations should be performed. The sequence stretch
of tridegin that probably interacts with FXIIIa has been localized in the C-terminal region of
the peptide.131,134 However, it is known that the presence of the N-terminal part enhances
inhibitor potency, but it remains unclear by what mechanism. This should be investigated in
a first step. Therefore, a series of peptides lacking different parts of the N-terminal region
should be synthesized and their inhibitory potency should be compared to the full length
inhibitor. The N-terminal part of tridegin also harbors six cysteine residues which are, to
current knowledge, fully oxidized to form three disulfide bonds. Both their function and
the pattern by which they are connected are not known. Therefore, tridegin analogues
lacking the disulfide bonds or the cysteine residues will be analyzed in more detail. All
enzyme activity assays are to be performed in cooperation with Prof. Dr. Torsten Steinmetzer
(University of Marburg).
For structural analysis, different approaches should be tested. Crystallization experiments,
which have unfortunately not been successful with pure synthetic tridegin in the past,
should be continued in presence of FXIII in cooperation with Dr. Manuel Than (FLI Jena).
Furthermore, the disulfide connectivity of tridegin should be investigated in parallel, to
learn about the number and type of disulfide-connected isomers present in the differentially
produced substances. To help this aim, a smaller peptide with all cysteine residues will be
synthesized and its disulfide pattern after oxidation will be evaluated. The method of choice
for this task should be a detailed MS and MS/MS analysis of the peptides. From the results,
a computational model of tridegin will be generated in cooperation with Dr. Arijit Biswas
(University Hospital Bonn).
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Once both functional and structural information have been gathered, these should be
combined and evaluated to derive structure-activity-relationships. Based on the structural
information derived from tridegin and the recently published structure of FXIIIa,149 computer
models of the tridegin-FXIIIa-interaction will be generated. The results are then to be
compared with the experimental data.
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4 Materials and Methods
4.1 Chemicals and Buffers
Table 4.1: Chemicals and reagents
Chemical Supplier
Solvents
Acetic acid Roth
Acetonitrile (HPLC grade) VWR
n-Butanol Roth
Dichlormethane (DCM, HPLC grade) VWR
Dimethylformamide (DMF, technical grade) VWR
Dimethylformamide (DMF, analytical grade) VWR
Ethyl acetate Roth
Isopropanol (HPLC grade) VWR
Methanol (HPLC grade) Fisher Scientific
Phenol FLUKA Chemika
Pyridine Riedel-de Haën
Water (HPLC grade) VWR
Reagents for peptide synthesis
Carboxyfluorescein (5-FAM) Novabiochem
N,N-Diisopropylethylamine (DIEA) ACROS
Ethandithiole FLUKA Chemika
O-benzotriazol-N,N,N’,N’-tetramethyl-uronium-hexafluoro-
phosphate (HBTU)
Iris Biotech GmbH
N-methyl-morpholine (NMM) Aldrich
Piperidine Sigma-Aldrich
Benzotriazol-1-yl-oxytripyrrolidinophosphonium
hexafluorophosphate (PyBOP)
Novabiochem
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Table 4.1: Chemicals and reagents (continued)
Chemical Supplier
Thioanisole FLUKA Chemika
Triflouroacetic acid (TFA, synthesis grade) Merck
Amino acid derivatives and resins
Fmoc-Ala-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Arg(Pbf)-OH,
Fmoc-Asn(Trt)-OH, Fmoc-Asp(OtBu)-OH,
Fmoc-Cys(Trt)-OH, Fmoc-Gln(Trt)-OH,
Fmoc-Glu(OtBu)-OH, Fmoc-Gly-OH, Fmoc-His(Trt)-OH,
Fmoc-Ile-OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH,
Fmoc-Met-OH, Fmoc-Orn(Boc)-OH, Fmoc-Phe-OH,
Fmoc-Pro-OH, Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-OH,
Fmoc-Trp(Boc)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Val-OH
ORPEGEN Pharma
Fmoc rink amide AmphiSphere 40 RAM PS PEG2000,
0.28 mmol/g
Varian
TentaGel amide resin, 0.24 mmol/g Intavis
Buffer components
Ammonium sulfate ((NH4)2SO4) Grüssing
Calcium chloride (CaCl2) Fluka
Dithiothreitol (DTT) Applichem
Ethylenediaminetetraacetic acid (EDTA) Roth
Glutathione, reduced (GSH) Sigma-Aldrich
Glutathione, oxidized (GSSG) Merck
Glycine Merck
Hydrochloric acid (HCl) Merck
Magnesium sulfate (MgSO4) Merck
Potassium dihydrogen phosphate (KH2PO4) Merck
Sodium chloride (NaCl) Roth
Sodium dihydrogen phosphate (NaH2PO4) Merck
Sodium dodecyl sulfate (SDS) Applichem
Sodium hydrogen phosphate (Na2HPO4) Fluka
Tricin Applichem
Tris(hydroxymethyl)aminomethane (Tris) Roth
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Table 4.1: Chemicals and reagents (continued)
Chemical Supplier
Electrophoresis reagents
Acrylamide, Bisacrylamide Applichem
Agarose (SeaKem™ LE) Lonza
Ammonium persulfate (APS) Applichem
Bromophenol blue Fluka
Coomassie brilliant blue G-250 Applichem
GelRed Biotium
Glutaraldehyde 25 % in water Merck
Glycerol (water free, 99 %) Grüssing GmbH
β-Mercaptoethanol Applichem
Page ruler unstained, Low Range Protein Ladder Thermo Scientific
Tetramethylethanediamine (TEMED) VWR
Amino acid analysis
Ready to use buffers A–F ONKEN
Ready to use Reagent R ONKEN
Sample dilution buffer (PVP) ONKEN
Proteins
Faktor XIII-A, Factor XIII-B, FXIIIa (recombinantly produced
in insect cells)
Zedira
Fibrogammin® CSL Behring
Cloning, nucleic acids and nucleic acid analysis
BioMix Red PCR master mix Bioline
BL21 (DE3) Singles™ competent cells Novagen
Clonables™ ligation/transformation kit Novagen
pEN08H (Trid.) Entelechon
pET22b(+) vector Novagen
T7 Promoter primer Novagen
T7 Terminator primer Novagen
ZR plasmid Miniprep™ Classic Zymo Research
Miscellaneous
Ammonia, 25 % in water Fluka
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Table 4.1: Chemicals and reagents (continued)
Chemical Supplier
Ampicilline Applichem
Iodoacetamide (IAA) Applichem
LB medium (Lennox) Applichem
Ninhydrin Chemapol
α-Cyano-4-hydroxycinnamic acid Sigma Aldrich
Peptide Calibration Standard Bruker
Phosphoric acid (H3PO4) Merck
Potassium idodide Fluka
Protein Calibration Standard I Bruker
o-Tolidine Serva
Table 4.2: Composition of buffers and media
Buffer Composition
SDS-PAGE cathode buffer 0.1 M tricine, 0.1 M Tris, 0.1 % SDS
SDS-PAGE running buffer 236 mM glycine, 25 mM Tris, 0.1 % SDS
SDS-PAGE sample buffer (2×) 150 mM Tris-HCl (pH 6.8), 1.2 % (w/v) SDS, 30 % glycerol, 15 % (v/v)
β-mercaptoethanol, 36 µg/ml bromophenol blue
M9 medium 33 mM Na2HPO4, 22 mM KH2PO4, 8.55 mM NaCl, 18.7 mM NH4Cl,
2 mM MgSO4, 0.1 mM CaCl2, 0.4 % glycerol and 100 µg/ml ampicillin
Coomassie staining solution150 0.1 % Coomassie brilliant blue G-250, 10 % ammonium sulfate,10 %
phosphoric acid, 20 % methanol
4.2 Peptide Synthesis and Purification
4.2.1 Solid-phase peptide synthesis
Solid-phase peptide synthesis (SPPS) was mainly performed at an automatic peptide syn-
thesizer (Economy Peptide Synthesizer EPS 221, ABIMED) using an Fmoc protecting group
approach. All peptides were synthesized as C-terminal amides using an Fmoc rink amide
AmphiSphere resin. The peptide synthesizer was programmed to perform the following
protocol (all amounts given for 100 mg resin):
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1. Preparation of the resin
• 1× rinsing with DMF I (2500µl)
• 1× rinsing with DCM (1400µl)
• 1× rinsing with DMF I (1400µl)
• 1× flushing with air (300µl)
• 1× rinsing with DMF I (2500µl)
2. Cleavage of the Fmoc protecting group
• 2× Fmoc-cleavage with 20 % piperidine in DMF (1000µl) – 6 min
• 1× rinsing with DMF I (4000µl)
• 1× rinsing with DMF I (1400µl)
• 1× flushing with air (300µl)
• 2× rinsing with DMF I (2000µl)
3. Coupling
• mixing of reagents in separate vial: 450µl HBTU, 125µl NMM/DMF (1:1), 10µl
DMF II und 420µl Fmoc-amino-acid in DMF
• 1× coupling – ca. 13 min
• mixing of reagents as above
• 1× coupling – ca. 13 min
• 1× rinsing with DMF I (3000µl)
• 2× rinsing with DMF I (1400µl)
• 2× rinsing with DMF I (2000µl)
4. Final Fmoc-cleavage and rinsing of resin
• 2× Fmoc cleavage with 20 % piperidine in DMF (1000µl) – 20 min
• 1× rinsing with DMF I (4000µl)
• 1× rinsing with DMF I (1400µl)
• 1× flushing with air (300µl)
• 2× rinsing with DMF I (2000µl)
• 4× rinsing with DCM (1400µl)
• 2× flushing with air (4500µl)
In cases where carboxyfluorescein coupling was required, this was done by manually after
automated synthesis of the unlabeled precursor. The resin was incubated with 2 eq. 5-FAM,
4 eq. PyBOP and 4 eq. DIEA for 1 h. After washing with DMF, the coupling was repeated for
maximum yield.
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Cleavage of peptides from the resin was performed as follows: Per 100 mg resin, 1 ml of
TFA (95 % in water) and 150µl “reagent K” (0.75 g phenol, 0.25 ml ethanedithiol, 0.5 ml
thioanisole) were added. The mixture was then incubated on the shaker for 3 h, then filtered
and precipitated in cold ether. Peptide pellets were washed three times with ether and then
redissolved in a suitable solvent.
4.2.2 Peptide oxidation
For the formation of disulfide bonds, the purified linear peptides were subjected to oxidative
folding in buffer. The reaction mixture contained the peptide at a concentration of 0.01 mM,
1 mM oxidized glutathione and 2 mM reduced glutathione in 40 % isopropanol and 60 %
buffer (0.1 M Tris-HCl, 1 mM EDTA, pH 8.7). All solvents were degassed for 15 min in an
ultrasonic bath and the reaction mixture was repeatedly evacuated and flushed with argon
after addition of every component. Finally, oxidative folding was performed under argon
atmosphere at 4 °C for 24 h.
4.2.3 Peptide purification and analysis by HPLC
Peptides were purified by high performance liquid chromatography (HPLC). Semi-prepa-
rative HPLC was performed on a LC 8A-system (SHIMADZU) equipped with an Eurospher
100 column (KNAUER, C18 reversed phase, 250×32 mm, 5µm particle size, 100 Å pore size)
for amounts between 20 and 100 mg and a Vydac 218TP1022 column (C18 reversed phase,
250×22 mm, 10µm particle size, 300 Å pore size) for amounts below 20 mg. For analytical
HPLC an LC 10AT-system (SHIMADZU) with a Vydac 218TP54 column (C18 reversed phase,
250×4.6 mm, 5µm particle size, 300 Å pore size) was used. All separations were done by
gradient elution and UV absorption was monitored at 220 nm. For details on gradients and
Table 4.3: HPLC methods applied for semi-preparative and analytical separations.
Method Flow rate Gradient (eluent B) Eluent A Eluent B
semi-preparative HPLC
method A 10 ml/min 10 %–60 % in 120 min 0.1 % TFA in
water
0.1 % TFA in 90 %
acetonitrile/watermethod B 10 ml/min 15 %–65 % in 120 min
method C 10 ml/min 20 %–70 % in 120 min
analytical HPLC
method D 1 ml/min 0 %–60 % in 60 min 0.1 % TFA in
water
0.1 % TFA in
acetonitrilemethod E 1 ml/min 20 %–60 % in 40 min
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4.3 Chemical Characterization of Peptides
eluents, please refer to table 4.3. Peptides (see section 5.1) were purified by the following
methods: P4, P7 and P18 with method A, P2, P15 and P5 with method B, P1, P15 with
method C. P3 was purified on analytical scale with method E. Peptide P6 was purified using
method C before and method A after oxidation.
4.3 Chemical Characterization of Peptides
Peptides were analyzed for purity by analytical HPLC, TLC and/or SDS-PAGE. Analytical data
is listed in table 4.4
4.3.1 Mass spectrometry
Mass spectrometry was performed at either a MALDI-TOF-device (Bruker Daltonics Autoflex
II) or at an LC-ESI-device (Bruker Daltonics MircoTOF-Q) coupled to a Dionex UltiMate 3000
LC system.
For MALDI measurements, the dissolved samples were mixed with an equal volume of
matrix solution (7 mg/ml solution of α-cyano-4-hydroxycinnamic acid in 50 % acetonil-
trile/water with 0.1 % TFA). Mixing was done either directly on the target plate or separately
in advance. A total of 2µl was spotted on the target plate and left to dry. The instrument was
calibrated prior to each series of measurements with Peptide Calibration Standard (Bruker)
for smaller (400-4000 Da) or Proteins Calibration Standard I for larger (up to 30 000 Da)
samples.
For ESI-measurements the samples were either directly injected into the source or pre-
separated by the coupled LC device on a Macherey Nagel NUCLEOSHELL column (C18 reversed
phase, 100×2 mm, 2.7µM particle size, 90 Å pore size). In this case, a solvent system of
water with 0.1 % acetic acid (eluent A) and acetonitrile with 0.1 % acetic acid (eluent B) was
used. The separation was done using a gradient of 0 % eluent B to 60 % eluent B in 12 min.
4.3.2 Amino acid analysis
Amino acid analysis was performed to determine peptide concentration in solutions and
peptide content in lyophilized powders. Peptide samples were freeze dried, dissolved in
6 N HCl and subsequently incubated at 110 °C for 24 hours to achieve total hydrolysis. The
samples were afterwards dried by vacuum centrifugation at 60 °C and redissolved in an acidic
sample buffer (PVP, as purchased from Orpegen). Amino acid analysis was then performed in
an amino acid analyzer (LC 3000, EPPENDORF-BIOTRONIK). For concentration determination
an external standard containing 200 nM of all detectable amino acids was used.
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Table 4.4: Chemical characterization of synthesized peptides. For HPLC methods please refer to table 4.3. tR: retention time, Rf: retardation factor TLC. PAGE
gives the apparent molecular weight in SDS-PAGE. If higher charged states than [M+H]+ were detected in MS, [M+H]+ was calculated from these.
Peptide Sequence
number
Length
(aa)
tR method E
[min]
Rf,1
a Rf,2
a PAGE
[kDa]
mass (calc.)
[Da]
mass ([M+H]+)
[Da]
Tridegin (full lenght)
Tridegin linear P1 66 22.4 0.56
system 1
0.49
system 3
7.1 7782.1b 7783.4b
Tridegin oxidized P2 66 20.4 0.50
system 1
0.47
system 3
8.0 7777.0b 7778.7b
Tridegin dimer P3 2×66 20.1 n.d. n.d. 8.1
16.1c
15554.0b 15553.5b
Tridegin recombinant P4 66 21.3 n.d. n.d. 8.4 7776.0b 7777.1b
Tridegin all-C-to-S P5 66 18.9 0.01
system 1
0.05
system 2
7.4 7685.8b 7688.3 b
Shorter derivatives
K01–C37 (N-terminal seg.) P6 37 20.0 n.d. n.d. 5.5 4255.9 4256.9
R38–E66 (C-terminal seg.) P7 29 13.7 0.01
system 1
0.09
system 2
5.1 3531.9 3532.9
A32–E66 P8 35 17.3 0.07
system 1
0.47
system 2
n.d. 4191.2b 4192.0b
D22–E66 P9 45 19.0 0.36
system 1
0.26
system 2
n.d. 5363.2b 5363.4b
C17–E66 P10 50 20.9 0.36
system 1
0.55
system 2
n.d. 5883.8b 5884.8b
a TLC systems: system 1: n-butanol/acetic acid/water 48:18:24, system 2: pyridine/ethyl acetate/acetic acid/water 5:5:1:3, system 3: t-butanol/ethyl acetate/acetic
acid/water 1:1:1:1
b average mass
c under non-reducing conditions
n.d.: not determined .
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Table 4.4: Chemical characterization of synthesized peptides. (continued)
Peptide Sequence
number
Length
(aa)
tR method E
[min]
Rf,1
a Rf,2
a PAGE
[kDa]
mass (calc.)
[Da]
mass ([M+H]+)
[Da]
I12–E66 P11 55 21.2 0.32
system 1
0.24
system 2
n.d. 6461.5b 6462.6b
E07–E66 P12 60 21.1 0.32
system 1
0.18
system 2
n.d. 7099.2b 7099.9b
L43–L60 P13 18 16.6 0.36
system 1
0.45
system 2
n.d. 2186.1 2191.6
L43–L60, Q52E P14 18 17.2 0.29
system 1
0.39
system 2
n.d. 2187.1 2188.0
Flourescence labeled peptides
cf-Tridegin linear P15 66 21.3 0.50
system 1
n.d. 7.1 8140.5b 8142.7b
cf-Tridegin oxidized P16 66 20.8 0.50
system 1
n.d. 7.1 8146.5b 8149.7 b
cf-N-terminal segment P17 37 23.0 0.54
system 1
0.62
system 2
n.d. 4617.0b 4618.1 b
cf-C-terminal segment P18 29 17.3 0.53
system 1
0.53
system 2
n.d. 3890.2 3892.0
a TLC systems: system 1: n-butanol/acetic acid/water 48:18:24, system 2: pyridine/ethyl acetate/acetic acid/water 5:5:1:3, system 3: t-butanol/ethyl acetate/acetic
acid/water 1:1:1:1
b average mass
n.d.: not determined.
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4.3.3 SDS-PAGE
For analysis of peptides by polyacrylamide gel electrophoresis (PAGE), resolving gels with
18 % acrylamide/bisacrylamide and 5 % crosslinking were prepared in 0.75 M Tris-HCl pH 8.4,
0.1 % SDS, 0.1 % APS, 0.05 % TEMED. Stacking gels contained 3 % acrylamide/bisacrylamide
with 3.3 % crosslinking and were prepared in 0.75 M Tris-HCl pH 8.4, 0.1 % SDS, 0.1 % APS,
0.1 % TEMED. Peptide solutions were mixed with an equal volume of SDS-PAGE sample
buffer and applied to the gel. The gel was allowed to run at a voltage of 45 V for 1 h and at
a voltage of 100 V for another 2-3h. The gels were fixed in 5 % glutaraldehyde for 30 min,
washed 3×5 min in water and prepared for staining in 45 % methanol, 10 % acetic acid at
60 °C for 30 min. Then staining was done with colloidal Coomassie staining solution over
night. Apparent molecular weights were determined with GelAnalyzer 2010a.
4.3.4 Ellman’s assay
Ellman’s assay was used to determine the concentration of free thiol groups in peptide
solutions. Ellman’s reagent (5,5’-dithiobis-(2-nitrobenzoic acid), DTNB) was prepared at a
concentration of 1.76 mg/ml in 0.2 M sodium phosphate buffer pH 8. In a microtiter plate,
150µl of sample or standard solution were mixed with 100µl of Ellman’s reagent. After
10 min, absorption at 410 nm was measured. For calculation of free thiol groups in solution,
a standard curve was prepared using a cysteine solution at concentrations between 3 and
167µM. The standard curve was linear in this range with R2>0.999.
4.4 Recombinant Expression of Tridegin
4.4.1 Cloning strategy
The recombinant expression of tridegin in Escherichia coli was performed according to Arkona
et al.151 As there was no access to the original DNA from Haementeria ghilianii, a synthetic
cDNA sequence was used. The cDNA, optimized for expression in E. coli, was purchased
from Entelechon (Regensburg, Germany). This sequence already contained the MscI and
BamHI restriction sites necessary for cloning into the pET22b(+) vector and was provided in
a pEN08H vector (see figure 4.1A). This vector was amplified in E. coli NovaBlue (Novagen)
cells. After purification of the vector with ZR Plasmid Miniprep Classic, the synthetic fragment
was excised, purified by agarose gel electrophoresis on a 1 % agarose gel and ligated into
pET22b(+) with Clonables™ligation/transformation kit (Merck Millipore). The synthetic
DNA fragment was designed in a way that ligation could be done in frame with the pelB-leader
sequence present in pET22b(+) ( see figure 4.1B). The success of the ligation was confirmed
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4.4 Recombinant Expression of Tridegin
A
B
Figure 4.1: Cloning strategy for recombinant tridegin. A: schematic depiction of the vectors. B: Sequences
of the multiple cloning site of the empty vector as well as the sequence of the synthetic cDNA. Restriction
sites are indicated in both sequences.
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by polymerase chain reaction (PCR), using T7 promoter and T7 terminator primers. The
PCR program was as follows:
1. Initialization – 95 °C, 4 min
2. Denaturation – 95 °C, 1 min
3. Annealing – 50 °C, 1 min
4. Elongation – 72 °C, 3 min
5. Final elongation – 72 °C, 10 min
6. Hold – 4 °C
Steps 2 to 4 were repeated for 30 cycles. The reaction was performed in BioMix Red
master mix and the reaction products were analyzed on a 1 % agarose gel containing GelRed
for visualization. The correct sequence of the ligation site was verified by DNA sequencing
(using T7 promoter primer, by GATC biotech). The sequence allows expression of a tridegin
variant carrying the N-terminal pelB-leader sequence for periplasmic localization. The vector
was again amplified in NovaBlue cells, purified and then transformed into competent BL21
(DE3) cells for expression.
4.4.2 Growth, harvesting and purification
The bacterial starter cultures were grown over night in LB medium and then M9 medium
was inoculated with the starter culture. The bacteria were allowed to grow at 37 °C until
an optical density of 0.4 at 600 nm was reached. Then the culture was induced by addition
of 1 mM IPTG and allowed to grow at 24 °C over night. The cells were then harvested by
centrifugation. For analysis of protein in the medium fraction, 1 ml of medium was mixed
with 5 ml of cold (-80 °C) acetone for precipitation of protein. After centrifugation, the pellet
was redissolved in SDS-PAGE sample buffer.
Preparation of the periplasmic fraction from the cell pellet was done by a protocol adapted
from the PeriPreps periplasting kit (Biozym Scientific, Germany). Per 1 g of wet cell pellet
4 ml of periplasting buffer (200 mM Tris-HCl, pH 7.5, 20 % sucrose, 1 mM EDTA and 30 U/µl
lysozyme) were added. The suspension was incubated at room temperature for 5 min, then
6 ml of cold (4 °C) water was added to induce an osmotic shock. After 10 min on ice the
mixture was centrifuged and the supernatant containing the periplasmic fraction was isolated.
All fractions were analyzed for tridegin by SDS-PAGE. As most of the peptide was found in
the medium fraction, this fraction was used for purification. The medium was freeze dried
and subsequently redissolved in 1/30 of the original volume in water. Insoluble particles
and substances were removed by centrifugation and the clear solution was purified by HPLC
method A (see table 4.3). Purity was confirmed by SDS-PAGE and analytical HPLC.
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4.5 Functional Assays
4.5.1 Chromogenic enzyme activity assay
The chromogenic enzyme activity assay was performed essentially as described.141,151 An ali-
quot of 100µl Fibrogammin®(6.25 U in total) was diluted with 500µl Tris-HCl-buffer pH 7.5
(50 mM), then 360µl 0.9 % (w/v) NaCl solution and 10µl 1 M CaCl2 solution were added.
Activation was started by addition of 1.42 U thrombin. After 20 min at 37 °C the reaction was
stopped by the addition of 10µl of a 1 mg/ml hirudin solution, thereby inhibiting further
thrombin activity. Measurements were performed on microtiter plates in a Labsystems iEMS
Reader MF spectrophotometer. Each measurement contained 50µl of the enzyme solution,
50µl of inhibitor solution, 100µl Tris-HCl buffer pH 7.5 and 50µl of a 400µM substrate
solution. The substrate used was H-Tyr-Glu(pNA)-Val-Lys-Val-Ile-Gly-NH2.
141 Absorption was
measured at 405 nm for up to 1 h. For evaluation of the data, OriginPro 8 was used.
4.5.2 Fluorogenic enzyme activity assay
Activation of FXIII for these measurements was done as above. For measurement of enzyme
activity by fluorescence, a novel fluorogenic substrate H-Tyr(3-NO2)-Glu(NH-(CH2)4-NH-
Abz)-Val-Lys-Val-Ile-NH2 · 3 TFA was used based on previous substrates.128 In contrast to the
chromogenic measurements, only 1/5 of the enzyme amount per measurement was required.
Otherwise, measurements were performed as above at a substrate concentration of 20µM. For
correct evaluation of enzyme kinetic parameters, an inner filter correction was necessary.152
For this purpose, the reference fluorophor 2-Abz-NH-(CH2)4-NH2 · 2 TFA was used to establish
a calibration curve for the fluorescence signal at different concentrations (0.05µM to 20µM).
Then, inner filter correction was performed by measuring the fluorescence of the substrate at
different concentrations (1µM to 20µM) in presence and absence of the reference fluorophor.
From this, a correction factor was calculated for each substrate concentration as described.128
Synthesis of the substrate and fluorophor as well as the inner filter correction were done by
T. Steinmetzer and K. Hardes (University of Marburg).
4.5.3 Microscale thermophoresis experiments
For binding studies on fluorescence labeled molecules in solution, Microscale thermophoresis
(MST) can be used. The method is based on differences in thermophoretic behavior that occur
when the size, hydration or charge of a molecule or complex is altered upon binding.153
For these studies, carboxyfluorescein-labeled inhibitor derivatives were synthesized and
incubated with varying concentrations of FXIIIa, FXIII-A and FXIII-B. The measurements
were done on a Monolith NT 115 instrument from Nanotemper (Munich, Germany). A
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solution of 62.5-250 nM carboxyfluorescein-labeled peptide was prepared in buffer (50 mM
Tris- HCl pH 7.5, 0.9 % w/v NaCl), finally 0.1 % Tween-20 was added. A serial dilution
of the unlabeled protein was performed in the same buffer (omitting Tween20) and was
then mixed with an equal volume of inhibitor solution. After incubation for at least 20 min,
the solutions were transferred into a glass capillary and thermophoresis was measured at a
IR-laser power of 50 %. The data were evaluated using NT analysis 1.2 and OriginPro 8G.
4.6 Structure Elucidation
4.6.1 Enzymatic digests and MS analysis
For structure elucidation, peptides were digested with chymotrypsin. Per 100µg peptide,
20µg chymotrypsin were added from a stock solution of 0.1 mg/ml chymotrypsin in 1 mM
HCl. Digests were performed in slightly acidic buffer (50 mM phosphate buffer pH 6.5)
to suppress disulfide shuffling. After incubation at 37 °C for 1.5 h reaction was stopped
by the addition of an equal volume of 0.1 % TFA. Samples were freeze-dried and either
analyzed directly by mass spectrometry or subjected to analytical HPLC separation (Method
D). Samples were collected from the analytical HPLC run and freeze-dried again. All samples
were analyzed on the MicroTOF Q device (see 4.3.1) before and after reduction with 10 mM
DTT in 10 mM phosphate buffer pH 8.5. Both MS and MS/MS experiments (CID) have been
performed. Evaluation of the MS and MS/MS data was done with BioTools (Bruker).
4.6.2 Molecular modeling
Molecular modeling and docking was done by A. Biswas (University Hospital Bonn). The
models of three different disulfide-linked isomers of tridegin were generated by restraining the
γ-S atom of the cysteine residues participating in disulfide bonds at a bond length of 2 Å. The
models were afterwards energy minimized and then refined by running a molecular dynamics
(MD) simulation for 500 ps (YAMBER force field). Then, the three different structures with
the energy minimum in the simulation trajectory were used for a blind docking to FXIII-A°
(after removal of ZED1301 from the crystal structure).149 Blind docking was done on a
Z-Dock docking server.154
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The results of this thesis are a direct continuation of a diploma thesis from 2010.53 The
results presented here have been published in two full articles in 2012151 and 2014155 and
represent the major contribution to this thesis. Furthermore, part of the work described
herein was published in a master thesis156 recently.
5.1 Design of Peptides
Earlier investigations on tridegin already established the synthesis of the compound134 as
well as some functional53,143 and structural53 characteristics. These results need to be taken
into account to derive compounds that would allow a more detailed exploration of the
characteristics of the inhibitor.
5.1.1 Potency of inhibitors from different preparations
The potency of tridegin has been studied previously in vitro with the help of a FXIIIa activity
assay.134,143 It was shown that the synthetic, fully oxidized tridegin had an IC50 value
between 0.3 and 0.6µM, while a recombinant variant was substantially more potent with an
IC50 of approx. 0.1µM. Different explanations for this discrepancy are possible. First, the
oxidation of recombinant tridegin, which was produced in E.coli, is assumed to take place in
the periplasm of the bacteria, to where it is exported in the expression process.142 This is
an environment significantly different from the oxidation buffer used in the production of
synthetic tridegin, especially concerning the presence of oxidoreductases and other enzymes.
Therefore, a different disulfide connectivity might result. Second, the recombinant tridegin
is reported to be a disulfide-linked dimer, which might also influence potency.
To address the question, how these different potencies (including the high potency of the
“native” tridegin described in the literature) arise, different tridegin variants were chosen.
First, a linear, synthetic analogue P1 was prepared, as well as the buffer-oxidized version
thereof (P2). Moreover, as a side product of this oxidation reaction, a synthetic, dimeric
variant P3 was isolated which would allow a direct comparison of monomeric and dimeric
tridegin from the same source. Additionally, the recombinant expression of tridegin P4 was
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necessary to validate the potency obtained with recombinant tridegin earlier. This results in
the following sequences:
KLLPCKEWHQ GIPNPRCWCG ADLECAQDQY CAFIPQCRPR
SELIKPMDDI YQRPVEFPNL PLKPRE
(P1)
oxidized version of P1 (P2)
oxidized, dimerized version of P1 (P3)
recombinant version of P1 (P4)
5.1.2 Influence of the N-terminal part on inhibitor function
In previous investigations it was shown that the N-terminal part (i.e. K1-Q36) did not
inhibit FXIIIa at all, while the C-terminal part (C37-E66) retained about 25 % of inhibitor
potency.53,134 While this indicates that the major inhibitor function resides in the C-terminal
part of the peptide, the reason for the approx. 4fold increase in potency in the presence of the
N-terminal part is still of interest. Also, the question arises how much this is influenced by
the oxidation state of the cysteine residues, which are concentrated in the N-terminal region.
Therefore, besides the linear peptide P1 and the oxidized tridegin P2, a variant where all
cysteine residues are exchanged for serine is needed, because this efficiently eliminates the
possibility to form disulfide bonds, which might still be present in P1 due to spontaneous
oxidation.
Furthermore, due to experimental reasons, the earlier studies on the isolated N- and
C-terminal parts of tridegin split the peptide sequence between Q36 and C37, leaving five
cysteine residues in the N-terminal part and one in the C-terminal part.134 Therefore, proper
disulfide formation was not possible in the N-terminal part, which might have influenced the
result concerning the inhibitory actions of this part. To correct this, two more peptides with
the structurally more reasonable split between C37 and R38 need to be synthesized (P6 and
P7). This leaves the following additional sequences necessary to investigate the function of
the N-terminal cysteine network:
KLLPSKEWHQ GIPNPRSWSG ADLESAQDQY SAFIPQSRPR
SELIKPMDDI YQRPVEFPNL PLKPRE
(P5)
KLLPCKEWHQ GIPNPRCWCG ADLECAQDQY CAFIPQC (P6)
RPRSELIKPM DDIYQRPVEF PNLPLKPRE (P7)
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5.1.3 Potency and substrate behavior of C-terminal peptides
The potency of different sequence stretches of tridegin has previously been studied on the
basis of a series of peptides derived from a C-terminal 30mer of the inhibitor (C37-E66) by
sequentially shortening this peptide by two amino acids (one in the N-terminus and one in
the C-terminus) down to an 8mer (D48-V55).53 The rationale behind this approach was to
find a minimal effective sequence around the I50 residue, that was established earlier as an
important position (see section 2.5.3).143 This investigation revealed that inhibitor potency
did not vary much when the 30mer was shortened to a 22mer and was only slighly impaired
in the 20mer and 18mer. However, further shortening the peptides resulted in significantly
decreased potency and both the 10mer and the 8mer showed almost no inhibition of FXIIIa
(Figure 5.1).53
Another finding came up in the course of the earlier performed investigation: all the
N-terminally truncated peptides showed a progress curve in the FXIIIa activity assay that
indicated that they were competing substrates rather than true inhibitors, which was not
the case for tridegin. From this finding it was concluded that the only glutamine residue
present in all peptides (Q52) was responsible for the substrate-like behavior of these peptides
in the presence of FXIIIa and that this position might be altered by either deamidation or
transamidation which then results in a non-inhibitory compound. To test this hypothesis, the
Q52 position was mutated in one of the model peptides to ornithine, glutamate and alanine.
All of the mutant peptides showed substantial loss of inhibitor potency, which supported the
Figure 5.1: IC50 values of peptides from the C-terminal part of tridegin. Modified from Böhm, 2010.
53
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theory.53
As a consequence of these findings, the question arises how long or short a sequence
stretch from tridegin must be to work as a substrate or a “true” inhibitor. Therefore, longer
peptides needed to be synthesized, which contain the full C-terminal region and truncated
N-terminally to different extent. The shortest of these peptides is the 35mer P8 and the
longest is the 60mer P12. Furthermore, two short peptides of the former series53 were
chosen to investigate the changes that occur in the presence of FXIIIa: the 18mer P13 and as
a comparison the deamidated version P14. In summary, the peptides chosen for investigation
of the substrate-behavior of the C-terminal tridegin sequence are:
AFIPQCRPRS ELIKPMDDIY QRPVEFPNLP LKPRE (P8)
DLECAQDQYC AFIPQCRPRS ELIKPMDDIY QRPVEFPNLP
LKPRE
(P9)
CWCGADLECA QDQYCAFIPQ CRPRSELIKP MDDIYQRPVE
FPNLPLKPRE
(P10)
IPNPRCWCGA DLECAQDQYC AFIPQCRPRS ELIKPMDDIY
QRPVEFPNLP LKPRE
(P11)
EWHQGIPNPR CWCGADLECA QDQYCAFIPQ CRPRSELIKP
MDDIYQRPVE FPNLPLKPRE
(P12)
LIKPMDDIYQRPVEFPNL (P13)
LIKPMDDIYERPVEFPNL (P14)
5.1.4 Binding affinity of tridegin analogues to FXIII
A question that has not been addressed so far is the binding affinity of tridegin or derivatives
towards different variants of FXIII. Binding affinity measurements are able to detect inter-
actions between the peptides and FXIII/FXIIIa even in the cases where no enzyme activity
can be measured. This allows to answer the question, whether or not tridegin or analogues
bind to inactive forms of FXIII, e.g. FXIII-A (non-activated) or FXIII-B. Furthermore, it can
be analyzed, whether peptides that do not exert inhibitory action on FXIIIa still bind to the
enzyme.
One binding assay capable of addressing these questions is microscale thermophoresis
(MST, see section 5.3.6), which requires one binding partner to be fluorescence-labeled. As
most of the peptides used here are prepared by solid-phase peptide synthesis, a labeling of the
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N-terminus with carboxyfluoresceine can conveniently be performed. Therefore, fluorescence-
labeled derivatives of linear and oxidized tridegin (P1 and P2) as well as the isolated N- and
C-terminal parts P6 and P7 were prepared resulting in the following analogues:
cf-KLLPCKEWHQ GIPNPRCWCG ADLECAQDQY CAFIPQCRPR
SELIKPMDDI YQRPVEFPNL PLKPRE
(P15)
oxidized version of P15 (P16)
cf-KLLPCKEWHQ GIPNPRCWCG ADLECAQDQY CAFIPQC (P17)
cf-RPRSELIKPM DDIYQRPVEF PNLPLKPRE (P18)
5.2 Preparation of Tridegin and Derivatives
Access to native tridegin – which has originally been extracted from the salivary gland of
Haementeria ghilianii – is very limited. Therefore, other ways of production have been
applied. As already described, solid-phase peptide synthesis is a fast and reliable way of
producing tridegin.134 However, there is also the possibility of recombinant production.131,151
Both ways to gain access to tridegin need to overcome the problem of oxidation, i.e. the
formation of three disulfide bonds in the tridegin structure. As the “native” disulfide linkage
of tridegin is currently unknown, both procedures were performed in a way that relied on
the self-folding capabilities of the peptide.
5.2.1 Synthesis
Synthesis of linear precursors All of the analyzed peptides, with exclusion of P4, were
prepared as linear precursors by standard solid-phase peptide synthesis. In case of the
carboxyfluoresceine-labeled peptides, after coupling of the last (i.e. most N-terminal) amino
acid, carboxyfluoresceine was coupled to the N-terminus. The yields for raw and purified
products are given in Table 5.1.
Peptide oxidation The oxidation of the linear precursors – when required – was carried out
in a glutathione-containing buffer, which is supposed to support folding of the peptide into its
energy minimized state and formation of disulfide bonds. However, in all cases when it was
applied (P2, P6, P16 and P17), oxidation was not finished after 24 h. Furthermore, in case of
P6, oxidation gave rise to multiple HPLC peaks with several of them containing fully oxidized
peptide (as determined by iodoacetamide derivatization and subsequent MS analysis). As
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Table 5.1: Yields of synthesized peptides (per 100 mg resin, loading capacity 0.28 mmol/g)
Yield raw product Yield purified product
Peptide Length (aa) [mg] [%] [mg] [%]
P1 66 73.4 33.7 15.2 7.0
P2 66 – – 2.9 19.31 (1.42)
P5 66 71.2 33.1 2.7 1.8
P6 (reduced) 37 40.3 33.8 2.4 2.0
P6 37 – – 0.7 29.21 (0.62)
P7 29 side product of P18 – –
P8 35 41.6 35.2 12.4 10.6
P9 45 72.8 48.5 7.4 4.9
P10 50 68.0 41.3 6.4 3.8
P11 55 76.4 42.2 7.0 3.9
P12 60 82.2 41.4 5.9 2.9
P13 18 52.3 99.6 12.5 23.8
P14 18 49.5 94.3 21.8 41.5
P15 66 128.0 56.1 4.7 2.0
P16 66 – – 0.7 14.91 (0.3)2
P17 37 – – 0.53 0.43
P18 29 37.0 33.9 0.9 1.7
1 oxidation step only. 2 whole synthesis. 3 raw product was oxidized directly
further oxidation even in the presence of oxygen did not change the HPLC profile, it was
concluded that the reaction had reached its equilibrium. Therefore, the oxidation product
was again purified by HPLC to remove partly oxidized product. Due to the low amount of
product after oxidation, yields could not be determined in all cases (table 5.1). Still, sufficient
amounts for functional analyses were generated.
Purification of a synthetic tridegin dimer The chemical synthesis of the linear tridegin pre-
cursor is followed by an oxidation protocol that has already been described in detail.53,134,143
It was also shown that the synthesized tridegin product after oxidation did not only con-
tain monomeric, oxidized tridegin, but also a reduction labile dimeric form and probably
some higher multimers.134 The formation of these dimers occurs randomly, if oxidation is
carried out in a self-folding procedure under oxidative conditions. Preferential formation
of monomer is achieved by a high dilution of the peptide during this process (in this case
10µM) thereby kinetically disfavoring multimer formation. However, formation of these side
products may still occur.
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A B
Figure 5.2: A) The gel filtration chromatogram shows the presence of dimeric tridegin (indicated by arrow) in
the synthetic tridegin preparation. B) SDS-PAGE performed under reducing and non-reducing conditions
proves that the isolated dimer is stable under denaturating conditions but labile in the presence of a reducing
agent.
It has been suggested by Coch143 that the dimer might have a higher inhibitory potency
compared to the monomer. Therefore it was isolated from the major, monomeric product
by gel filtration chromatography (Figure 5.2A). This was done in cooperation with M. Than
(FLI Jena), to whom tridegin was provided for crystallization experiments and who kindly
returned the dimeric side fractions after purification of the monomer. These fractions
were then purified and desalted by HPLC, which resulted in a pure dimeric tridegin (P3)
preparation. With SDS-PAGE it was shown that the dimer is indeed labile in the presence of a
reducing agent (β-mercaptoethanol), but stable in the presence of the denaturating detergent
SDS (Figure 5.2B). This indicates that the dimer is covalently cross-linked by disulfide bonds.
Mass spectrometry after iodoacetamide treatment confirmed that the dimer is fully oxidized.
5.2.2 Recombinant expression of tridegin
The lacking knowledge of the “correct” disulfide connectivity of tridegin made it necessary
to explore an alternative way of preparation, i.e. the recombinant expression of the peptide,
as well. As an expression host, E. coli was selected. The bacterial cytoplasm does not
provide a suitable oxidative environment for disulfide formation, therefore a pelB leader
sequence was added to the N-terminus of the peptide sequence, which translocates the
polypeptide chain to the periplasmic space. During this translocation, the leader sequence
is removed. In the periplasmic compartment, oxidoreductases are present, which assist in
disulfide formation.157
Due to the fact that there is no published DNA sequence of tridegin from H. ghilianii, an
artificial DNA sequence was generated from the known peptide sequence and optimized
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A B
C
Figure 5.3: Recombinant expression of tridegin. A) DNA gel electrophoresis of PCR products. M: Marker,
Ctr: empty vector, * correctly ligated clones, ** probable re-ligation of empty vector, ° no detection of vector.
B) SDS-PAGE of different fractions after tridegin expression. Tridegin (ca. 10 kDa) can be found primarily in
the periplasmic and medium fractions. The prominent band at 14 kDa in the periplasmic and speroblastic
fraction is lysozyme, which was added in the purification procedure. C) DNA sequencing of the expression
vector confirmed the correct ligation at the MscI ligation site.
for expression in E. coli (Entelechon, Germany) which was then cloned in a suitable expres-
sion vector that already contained the periplasma localization sequence (pelB leader, see
section 4.4.1 for sequences). Subsequent analysis by PCR was used to identify clones that
carried the correctly ligated vector and DNA sequencing revealed that in-frame ligation of
the pelB leader and the tridegin sequence was indeed successful (Figure 5.3A and C). After
transformation into the expression host, tridegin production was confirmed by SDS-PAGE
of the medium and the periplasmic and spheroblastic fractions, showing predominantly
monomeric tridegin (Figure 5.3B). The correct processing, i.e. cleavage of the pelB leader
sequence upon translocation into the periplasma and the full oxidation of the product were
verified by MALDI-MS of the crude extract as well.
50
5.3 Functional Characterization
Tridegin was expressed without a purification tag to keep the recombinant sequence
identical to the synthetic variant (the only difference being the free C-terminus in the
recombinant tridegin). However, this made purification more challenging. An experiment
to fractionate the periplasmic extract by gel filtration chromatography and subsequent
purification by HPLC revealed, that after the gel filtration procedure tridegin was isolated as
a dimer. This effect was attributed to the neutral pH used for gel filtration (pH 7.0, 50 mM
phosphate buffer, 150 mM NaCl), which might have allowed disulfide shuffling. Since the aim
was to extract tridegin in the fold generated in the E. coli periplasm, this purification procedure
was discarded. Instead, purification was carried out by direct HPLC of the concentrated
medium fraction. This resulted in the purification of monomeric recombinant tridegin.
With this protocol, approx. 300µg of pure recombinant tridegin were isolated from 600 ml
medium, which corresponds to a yield of 0.5 mg per liter culture. The recombinant peptide
was used for further structural and functional investigations.
5.3 Functional Characterization
5.3.1 Substrate behavior of C-terminal peptides
It has been shown previously that isolated peptides from the C-terminal part of tridegin are
substrates for FXIIIa, and that the resulting product no longer shows inhibitory potential.53 It
was then assumed that Gln52 is the residue responsible for this substrate behavior and that
it is deamidated by FXIIIa or, in the presence of a small amine such as glycine ethyl ester (H-
Gly-OEt), transamidation occurs. However, the experiment proving this was still missing and
was therefore performed in the following step in cooperation with T. Steinmetzer (University
of Marburg). FXIII from Fibrogammin was activated with thrombin and incubated with a
short peptide stretch from the C-terminal part of tridegin (L43-L60, P13) in the presence and
absence of H-Gly-OEt. The results were compared with a peptide variant, in which Gln52
was substituted by Glu52, i. e. the suspected reaction product (P14). Both peptides (P13 and
P14, for sequences see section 5.1.3) have been synthesized and characterized in previous
works.53
The analysis revealed that P13 is indeed modified by FXIIIa both in the presence and
absence of H-Gly-OEt (Figure 5.4). Comparison of the reaction product (in absence of
H-Gly-OEt) with P14 showed similarity in retention time. Mass spectrometric analysis of the
reaction products confirmed the hypothesis that P13 can indeed be coupled to H-Gly-OEt by
FXIIIa. Furthermore, analysis of HPLC peak areas after different time points showed that
incorporation of H-Gly-OEt occurred much faster than deamidation of the substrate.
Interestingly, incubation of tridegin (P2) with FXIIIa did not result in a decreasing inhibitory
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Figure 5.4: HPLC of FXIIIa-catalyzed modification of P13 in the presence and absence of H-Gly-OEt. A)
activated fibrogammin, B) pure P13, C) pure P14, D) incubation of P13 with FXIIIa for 90 min in the presence
and E) in absence of H-Gly-OEt. The asterisk indicates the Glu(Gly-OEt)-containing product.
potency, both in the presence and absence of H-Gly-OEt. Also, no transamidation could
be detected. It was concluded that a part of the N-terminal region of tridegin did either
prevent or slow down a reaction with FXIIIa or retain the inhibitory function of the de-
/transamidated inhibitor. To evaluate this, a series of N-terminally truncated peptides was
synthesized, ranging from 35 to 60 amino acids in length (P8-P12).
5.3.2 Evaluation of N-terminally truncated peptides
The truncated peptides P8-P12 were synthesized as linear (reduced) peptides, because none
of them contained all cysteine residues present in tridegin and therefore oxidative folding
would not result in the correct disulfide connectivity. After purification, stock solutions were
prepared in water at concentrations between 0.3 and 2.0 mM and the oxidation state of
cysteine residues was assessed with Ellman’s test. This showed that the peptides were still
predominantly in reduced state (77 % reduced for P8, 90 % for P9, 97 % for P10, 100 % for
P11 and 95 % for P12). All peptides were studied with the help of a chromogenic enzyme
activity assay.141 The shape of progression curves was evaluated to determine, whether the
substrate-like behavior was similar to that of the shorter C-terminal peptides (see section 2.5).
A linear progression curve indicates a constant enzyme activity and stability of the inhibitor,
while a progression curve with increasing slope is explained by the turnover of the inhibitor
into a species with no or lower inhibitory potency.
Surprisingly, all of the synthesized peptides showed non-linear progression curves (Fig-
ure 5.5A). Inhibition of FXIIIa was strongest in the beginning of the measurement and
decreased over time. Full enzyme activity was not regained during the course of the mea-
surements, indicating that the reaction product (probably again a deamidated variant of the
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A B
Figure 5.5: A) Progress curves showing enzymatic activity in the presence of some of the N-terminally
truncated peptides (12.5 µM of P8 and P9, 10 µM of P12). Ctr.: control without inhibitor. The curves show
strong inhibition (i.e. substrate competition) in the beginning, but inhibition is almost completely lost later on.
B) IC50-values of the N-terminally truncated peptides (determined from the initial, linear range in the progress
curves).
peptides) did still retain a low inhibitory potency. Nevertheless this result was unexpected,
as the aim of the experiment had been to find a “threshold” length at which a true inhibitory
behavior as seen in full-length tridegin would occur. Therefore the experiment led to the
conclusion that either the mentioned “threshold” length was higher than the longest peptide
P12 (60 aa) or that the observed substrate behavior did not depend primarily on peptide
length, but on the three dimensional oxidized structure of the N-terminal region in full-length
tridegin. Therefore, this question was addressed separately (see section 5.3.3).
Furthermore, IC50 values were determined for all peptides using the linear range in the
progress curves at the beginning of the measurement. The IC50 values for peptides P8
to P12 ranged between 1.7µM and 3.0µM without any correlation with peptide length
(Figure 5.5B). This was expected, as earlier experiments already showed that an increase in
the length of the C-terminal part did not change IC50 values strongly at a length higher than
24 amino acids. The IC50 values of peptides P8 to P12 can therefore be regarded as similar
and deviations can at least partially be attributed to the fact that spontaneous oxidation of
the peptide might occur in the assay environment, thereby influencing the inhibitory potency
in a yet unknown way.
5.3.3 Inhibitory potency of different tridegin variants
For further elucidation of structure-activity-relationships, different tridegin variants were
analyzed by an enzyme activity assay. One question that arose from the previous investigations
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on tridegin-derived N-terminally truncated peptides was, how the N-terminal part of tridegin
functioned in preventing the inhibitor from being “inactivated” by FXIIIa. Therefore it was
of interest, whether the mere presence of the full N-terminal sequence was sufficient to
stabilize the inhibitor in the presence of FXIIIa, or whether oxidation of the cysteine residues
was required. To analyze this, three tridegin variants were compared: full-length oxidized
tridegin (P2), full-length linear tridegin (P1) and a full-length tridegin variant, in which
all cysteine residues were exchanged for serine (P5) to effectively exclude any possible
oxidation. Evaluation of the IC50-values revealed that P2 indeed had the highest potency
(IC50 ca. 0.5µM), while P1 and P5 displayed IC50-values of 1.5µM and 2.1µM, respectively.
The difference between P1 and P5 is probably not significant, especially since a slow or
partial oxidation of P1 under the assay conditions can be expected. This leaves a final 3-4-fold
decrease in IC50 that can be attributed to the oxidative folding of the N-terminal part of the
peptide. Surprisingly, peptide oxidation or the presence of cysteine residues in general did
not influence the inhibitory behavior compared to full-length oxidized tridegin, i.e. no loss
of inhibitory action was seen in peptides P1, P2 or P5. Therefore it can be concluded that
the oxidation of cysteine residues does increase inhibitor potency, but is not required for
inhibitor stability in the presence of FXIIIa (Figure 5.6).
Moreover, the influence of the production technique (i.e. recombinant vs. synthetic) and
the dimerization on the IC50 values of the inhibitor were analyzed. In contrast to former
findings,151 where recombinant tridegin was most active with an IC50 value of 40 nM,
142
the recombinant tridegin P4 showed an IC50 of about 1.2µM, which is twice as high as
for P2. However, the dimeric tridegin P3 was significantly more potent than the monomer
A B
Figure 5.6: A) Progress curves showing enzymatic activity in the presence of selected tridegin derivatives.
Ctr.: control without inhibitor. The curves are nearly linear. B) IC50-values of selected peptides in comparison.
n.a: not active.
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with an IC50-value of 0.11µM. This value is calculated with the correct molecular weight
of the dimer, when adjusted to “per monomer”, the IC50 is 0.22µM, which is still about
twice as potent as the synthetic monomer. From these two findings it was concluded that
the higher potency that was originally described for the recombinant tridegin can at least
partially be attributed to the dimeric form of this earlier preparation.151 The fact that it is
still slightly less potent than the synthetic variant P2 might be correlated with a different
distribution of disulfide-linked isoforms in both preparations, as will be discussed in more
detail in section 5.4.4. Why the potency of the dimer is higher than that of the monomer
remains unclear. However, these results indicate that the dimer might be the “native” form
of tridegin.
In earlier studies it was already suggested that the N-terminal part alone was not capable
of inhibiting FXIIIa.151 However, the variant used in this study was not oxidized since it
lacked one cysteine residue (C37), which is why the experiment was repeated with the
oxidized, isolated N-terminal part of tridegin (P6). It was shown that also the oxidized
isolated N-terminal part does not inhibit FXIIIa to a measurable degree (IC50>50µM). For
reasons of comparison, the corresponding C-terminal part of tridegin (P7), which was not
part of the formerly tested peptide series, was analyzed as well and revealed an IC50-value
of 2.2µM which is in accordance with what has been found for tridegin-derived peptides of
similar length and sequence (see section 2.5).53
One further tridegin derivative that was tested was a carboxyfluoresceine-labeled variant
of oxidized tridegin (P16). This was done in preparation of binding assays, in which P16
was to be used to assess binding to FXIIIa. The enzyme activity assay was supposed to show,
whether the fluorescence label influenced inhibitory action of tridegin. Indeed the IC50-value
of this variant was 5.2µM, which is about 10-fold worse compared to the unlabeled variant.
However, as the inhibitor was still working, this variant was applied for later binding studies,
keeping in mind that the detected binding might be weaker than for the unlabeled P2.
5.3.4 Assessment of a fluorogenic FXIIIa assay
In addition to the chromogenic enzyme activity assay that was used to determine all IC50-
values, a novel fluorogenic enzyme activity assay was tested. Therefore, a FRET (Förster
resonance energy transfer) substrate was applied. It carries the fluorophore 2-aminobenzoic
acid (Abz) in the glutamate side chain and the quencher 3-nitrotyrosine directly adjacent
to it in the N-terminus of the following sequence: H-Tyr(3-NO2)-Glu(NH-(CH2)4-NH-Abz)-
Val-Lys-Val-Ile-NH2 · 3 TFA.155 Upon cleavage of the Abz-glutamine-bond by FXIIIa, the
fluorophore is released and separated from the quencher, resulting in increasing fluorescence.
In comparison to former fluorogenic substrates, this substrate is conveniently synthesized
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Figure 5.7: IC50 determination of tridegin with A) a chromogenic and B) a fluorogenic assay. Curves were
fitted with a three parameter logistic model.
and shows a Michaelis constant Km of 2.5µM, which is more than 15-fold lower than the Km
of the chromogenic substrate (44 µM).141
Oxidized tridegin P2 was analyzed with both assays in comparison and IC50-values were
determined as shown in Figure 5.7. The IC50-value is about 2-fold lower for the fluorogenic
(0.30µM) compared to the chromogenic assay (0.68µM). This is in itself not surprising,
because the IC50 is, in contrast to Ki , strongly dependent on assay conditions. However, for
the classical inhibition types (competitive, non-competitive and uncompetitive) equations
have been derived that allow the calculation of Ki from IC50-values using the Michaelis
constant Km and the substrate concentration [S].158 For competitive inhibition, for example,
the relationship is as follows:
Ki =
IC50
[S]
Km
+ 1
(5.1)
For uncompetitive inhibition, in contrast, Ki is calculated:
Ki =
IC50
Km
[S] + 1
(5.2)
and for non-competitive inhibition:
Ki = IC50 (5.3)
Application of these equations to calculate Ki of tridegin from both the chromogenic and
the fluorogenic measurements results in the values given in Table 5.2. As can be seen from
this table, for none of the classical inhibition types a similar Ki was found for both assay
types, which would be expected if one of these pure inhibition types would apply to the
tridegin FXIIIa interaction. This indicated that tridegin might display a mixed inhibition type.
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Table 5.2: Calculation of Ki values for tridegin using different assays and inhibition types.
Assay [S] [µM] Km [µM] IC50 [µM] Ki
competitive uncompetitive non-competitive
Chromogenic 80 44 0.68 0.24 0.44 0.68
Fluorogenic 20 2.5 0.30 0.03 0.27 0.30
5.3.5 Inhibition type and stoichiometry of the tridegin-FXIIIa-interaction
To further investigate the inhibition type, an analysis with different substrate concentrations
was carried out with both assays. The aim of this investigation was to generate a Dixon plot
that would allow to determine inhibition type and Ki . Three different substrate concentrations
were tested in both assays, which were roughly 1×, 2× and 5× Km. The reaction velocity v
was derived from the progress curves and 1/v was plotted over the inhibitor concentration
according to Dixon.159 Unexpectedly, the resulting curves were not linear, but showed a shape
similar to an exponential or potential relationship. For the FRET-substrate this is depicted in
Figure 5.8A. A possible explanation for this is deviation from the 1:1 stoichiometry between
enzyme and inhibitor that is usually assumed in standard inhibitory models. A model for an
enzyme capable of binding two molecules of the same inhibitor in a random manner has been
suggested by Segel,160 and recently an example for a similar mechanism has been shown by
Kovalevsky et al. with small-molecule inhibitors of HIV-protease (Figure 5.8D and E).161 In
this case, a strong cooperativity between the two inhibitor binding sites was assumed. The
results reported in the study on HIV protease are similar to the findings for tridegin in that
the Dixon plot is non-linear.
To test the hypothesis of an alternate stoichiometry, another graphical representation was
used: the re-plotting of the slopes of Lineweaver-Burk-plots. For this, Lineweaver-Burk-plots
were generated by plotting the reciprocal velocity (1/v) versus the reciprocal substrate
concentration (1/[S]). The slope of the resulting linear curves is then again plotted versus
the corresponding inhibitor concentration. In case of a 1:1 stoichiometry of enzyme and
inhibitor, this re-plot is expected to be linear, while for a 1:2 stoichiometry a parabolic shape is
expected.160 Although the data presented is error prone, due to the low number of substrate
concentrations tested, the non-linearity of the re-plot is obvious in Figure 5.8B. However,
fitting of the data points to functions suggested by Segel or Kovalevsky was not successful,
either due to low data quality or a possible deviation from the described models.
To analyze the correct binding stoichiometry, a Hill-plot was generated. In this case, the
reaction velocity at a certain inhibitor concentration (vi) and the reaction velocity in absence
of the inhibitor v0 are used to calculate log(vi/(v0 − vi)) and to plot this value versus the
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A B
C D
E
Figure 5.8: Analysis of FXIIIa-tridegin stoichiometry. A) Dixon plots are non-linear for all three FRET-substrate
concentrations. B) Re-plotting the slope from Lineweaver-Burk plots versus the inhibitor concentration is
non-linear as well, suggesting a stoichiometry different from 1:1. C) Determination of the slope in the Hill plot
is used to estimate a 1:2.3 stoichiometry. D) Model with random sequence of inhibitor binding proposed by
Segel (modified).160 E) Inhibition model found for Darunavir inhibition of HIV protease by Kovalevsky et al.
(modified).161
logarithm of the inhibitor concentration log[I]. From the negative slope of the plot, the
stoichiometry can be estimated. In case of oxidized tridegin P2 a slope of 2.3 was found,
which suggests a 1:2 stoichiometry between enzyme and inhibitor (Figure 5.8C).
Re-evaluation of the data for the dimeric tridegin was performed next, to test, whether the
dimer P3 shows a 1:1 stoichiometry, which was, however, not the case. Stoichiometry for the
dimer was comparable to the results found for the monomer. Instead, a 1:1 stoichiometry
was found for the isolated C-terminal part P7 (Figure 5.9) as well as for the other short
C-terminal derivatives tested previously (data not shown).53 This indicates that the shorter
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A B
Figure 5.9: Hill plots of A) the dimer P3 and B) the C-terminal peptide P7.
derivatives do not only show the discussed substrate behavior, but also bind to FXIIIa in a
different way and stoichiometry than the full-length variants.
In conclusion, these analyses revealed that tridegin is not a “simple” competitive inhibitor,
as was initially expected. In contrast, the inhibition mechanism seems to be very complex
and can, with the data available, not be described with any of the standard models.
5.3.6 Binding studies
Binding studies were performed to show the binding affinity of different tridegin-derived
peptides to FXIII. In total, four peptides (P1, P2, P6 and P7) were prepared as N-terminally
carboxyfluoresceine-labeled variants (P15, P16, P17 and P18, respectively). Binding studies
were performed by microscale thermophoresis. The labeled peptide was kept at a constant
concentration and concentration of the protein was varied. In total three different forms of
FXIII were tested: FXIIIa, FXIII-A (inactive) and FXIII-B. While none of the peptides bound
to the inactive FXIII-A or the carrier B-subunits FXIII-B, all four showed binding to FXIIIa.
For three of the peptides, P16, P17 and P18, Kd values could be estimated from the binding
curves (Figure 5.10). For P16 and P17, Kd values were in the range of <100 nM, while
for P18 a Kd of ≈800 nM was found. For P15, no Kd value could be derived, because the
binding curve did not reach saturation under given condition. As all these measurements
were performed only once, one can not yet rely on the quantitative results, but the question
whether binding does occur can be answered in the cases analyzed here.
While binding of oxidized tridegin P16 to FXIIIa was expected, the strong binding of the
non-inhibitory N-terminal part P17 was surprising. In comparison, the binding affinity of the
C-terminal part P18 to FXIIIa was relatively low. However, this value might not reflect the
true binding affinity, since P18, like the other C-terminal derivatives, probably is a substrate
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Figure 5.10: Binding curves from MST experiments for A) P16 (Kd<100 nM), B) P17 (Kd<100 nM) and C)
P18 (Kd ≈800 nM) to FXIIIa.
which is transformed rapidly in the presence of excess FXIIIa. Therefore, this value might
represent the binding affinity of the corresponding Glu52 peptide. Future experiments will
help to answer this question.
In general, the binding assay suggests a strong contribution of the N-terminal region
to binding of tridegin to FXIIIa. However, due to limited availability of substances and
equipment, experiments have been done only once and a repetition or confirmation with
another binding assay is required to derive final conclusions. Anyway, these findings are
higly interesting with respect to the discussion of a mixed binding/inhibition mode.
5.4 Structural Analysis
Elucidation of the three dimensional structure of tridegin was of major importance for
structure-activity-relationship studies. Experiments with circular dichroism (CD) measure-
ments had already been performed in earlier investigations on the tridegin structure.53 This
estimation of secondary structures in tridegin (Figure 5.11) predicted low percentages of
α-helices and β-sheets and a high amount of β-turns and unordered structures. However,
CD is only a very rough method for secondary structure determination, and without detailed
knowledge on the disulfide bonding of tridegin, the overall fold of the peptide cannot be
determined. Therefore, methods that would give more detailed structural insights were
required.
Basically, three different methods for this were considered: 2D nuclear magnetic resonance
(NMR) spectroscopy, crystallization with subsequent X-ray structural analysis and elucidation
of the disulfide connectivity via mass spectrometry with subsequent molecular modeling.
The idea to perform NMR spectroscopy, although successful with other disulfide bridged
peptides such as hirudin165 and conotoxins,166 was not pursued further due to two reasons:
1) tridegin tends to form aggregates at concentrations higher than 1 mg/ml and 2) the purity
of the compound, especially with respect to the disulfide connectivity, was not clear, which
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CDNN ACDP
α-Helices 0.051 0.000
β-Sheets 0.126 0.000
– thereof parallel 0.107 n.d.
– thereof anti-parallel 0.019 n.d.
β-Turn 0.326 0.300
Aromatic/Disulfide bonds n.d. 0.030
Unordered 0.510 0.660
Total 1.014 0.990
Figure 5.11: Left: Measured (black) and fitted (red) CD-spectrum of tridegin. Right: Results of secondary
structure prediction based on CD-data. Two software packages were used: CDNN162 and ACDP.163,164
Modified from Böhm, 201053
would complicate the already challenging assignment of a 66-mer peptide. Therefore, efforts
were concentrated on crystallization experiments and MS analysis including subsequent
modeling studies.
5.4.1 Crystallization and co-crystallization experiments
Crystallization experiments were performed by Dr. M. Than (FLI Jena) and coworkers.155
First, crystallization of pure tridegin was attempted. Synthetic tridegin was purified from
the oxidized product and concentrated up to 1 mg/ml. Higher concentrations were not
possible due to above mentioned risk of aggregation and precipitation. Approximately 300
crystallization experiments at nanoliter scale were performed and promising conditions were
evaluated in subsequent finescreens. However, no peptide crystals were formed. This could
be either due to insufficient purity of the peptide (e.g. the presence of different isomers) or
a too flexible peptide structure.
In order to stabilize the tridegin structure and thereby help tridegin crystallize, co-
crystallization with the target protein was tried. Co-crystallization of tridegin with FXIIIa
had already been attempted without success and was therefore not repeated.167 However,
earlier reports from Arkona et al. suggested that tridegin also bound to inactive FXIII.142,151
The binding data discussed in section 5.3.6, which does not support binding of tridegin to
FXIII, was not available at the time. As crystallization of FXIII alone occurs readily and has
been done several times in the past,37,40 it was assumed that crystallization of a tridgin-FXIII-
complex was feasible. To assess, whether tridegin and FXIII form a stable complex in solution,
the molecules were analyzed both separately and in mixture by gel filtration chromatography
61
5 Results and Discussion
A B
Figure 5.12: Gel filtration chromatogram of A) FXIII and tridegin and B) a FXIII/tridegin 1:1 mixture. Fractions
were collected and analyzed by SDS-PAGE (silver stain). The higher molecular weight fractions in the mixture
B did not contain tridegin, i.e. no stable complex could be isolated.
(Figure 5.12). However, the complex, if formed, was not stable enough to be isolated by this
method. Therefore, co-crystallization experiments were performed at varying tridegin:FXIII
ratios (between 1.3:1 and 5:1) to facilitate complex formation. Again, several thousand
crystallization experiments and subsequent finescreens were performed which resulted in
a variety of crystals. Analysis of these crystals revealed, however, only the presence of the
already known FXIII structure with no additional electron density, indicating the absence
of tridegin. The reason for the absence of co-crystals is suggested to be caused by the low
binding affinity of tridegin to FXIII, which has been shown later by a binding affinity assay.
Yet also other factors might be critical, such as the presence of different disulfide-linked
isomers, which may also also explain the contradictory findings on whether or not tridegin
binds to FXIII.
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5.4.2 Elucidation of disulfide connectivity
In parallel to the aforementioned crystallization experiments, elucidation of disulfide con-
nectivity by mass spectrometry was performed. There are different possibilities for disulfide
bridge determination via MS or MS/MS including partial reduction and alkylation,168 enzy-
matic digest and subsequent MS(/MS) analysis169 as well as direct MSn fragmentation.170
For elucidation of the disulfide connectivity in tridegin, an enzymatic digest protocol was cho-
sen.169 Analysis of possible cleavage sites in the tridegin sequence revealed that chymotrypsin
was the most suitable enzyme for this purpose. Chymotrypsin cleaves C-terminal of aromatic
residues (tryptophane, phenylalanine and tyrosine) as well as methionine and leucine. This
means that in between two cysteine residues of the tridegin sequence there is at least one
possible cleavage site (Figure 5.13). The enzymatic digest protocol was then optimized
using linear tridegin (P1). Samples were taken at different time points during incubation at
37 °C and analyzed by HPLC, MS and MS/MS. An incubation time of 1.5 h was then selected,
which yielded a low number of unspecific cleavages and showed some incompletely digested
fragments that might be useful for structure elucidation. The digest was then repeated with
oxidized full-length tridegin (P2) and analyzed by HPLC, both before and after reduction
with DTT (Figure 5.13). The oxidized tridegin digest should, after reduction, show the same
fragments as the linear tridegin digest, if all digestion sites have a similar accessibility in both
oxidized and reduced state (Figure 5.13B and C). Although there are some differences in
the HPLC profile of both samples, the overall pattern is similar, which shows that the digest
is not significantly impaired in the oxidized peptide. However, differences between these
samples and the oxidized digest (Figure 5.13A) are obvious. Therefore it was concluded that
chymotryptic digest of the oxidized peptide was a suitable way to prepare disulfide-linked
fragments.
To reduce complexity of the digest, fractions were collected from the HPLC analysis,
concentrated by lyophilization and subjected to ESI-MS analysis both before and after
reduction with DTT. By comparing the MS spectra, mass peaks that were present in the
non-reduced and absent in the reduced samples were identified. These were the potential
disulfide-containing fragments. When analyzing the corresponding reduced sample, one
could find either a 2 Da heavier mass peak in case of a disulfide bond within one fragment,
or two new mass peaks corresponding to two fragments that were originally linked by a
disulfide bond (Figure 5.14). As can be seen, unspecific cleavage was also detected, especially
after arginine residues. The reason for this is not known, however, a contamination of the
chymotrypsin with trypsin is suspected. Figure 5.14B shows that the tridegin sequence has
been covered completely by this approach.
To ensure a correct assignment of the fragments and resolve remaining ambiguities,
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Figure 5.13: A) Cleavage sites for chymotrypsin in tridegin. B-D) HPLC traces (method D) of chymotryptic
digest of B) linear tridegin P1, C) oxidized tridegin P2 and D) oxidized tridegin P2 and reduction of digest
with DTT. *DTT.
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A
B
C
Figure 5.14: Analysis of the chymotryptic digest of oxidized tridegin P2. A) HPLC trace (method D) of
P2 digest with identified fragments. B) All detected fragments for P2. Cysteine containing fragments are
indicated above, cysteine-free fragments below the full-length sequence. C) Concluded isomers.
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fragments were analyzed in more detail by collision-induced dissociation (CID) MS/MS.
One of these ambiguities is exemplified in Figure 5.15: The potential oxidized fragment
C19GADLEC25A has a calculated [M+H]+ ion mass of 779.270 Da, whereas oxidized C31AFI-
PQC37 has an [M+H]+ ion mass of 779.322 Da. An ion mass of 779.270 was detected,
however, the theoretical mass difference of 0.052 Da is too low to be distinguished with
sufficient certainty. Both possible peptides show a mass increase of 2 Da when reduced, which
does not allow differentiation just by analyzing reduced samples. Therefore, fragmentation
patterns of both the oxidized and reduced species were analyzed. The fragmentation of
the oxidized species did yield very few fragments, only one C-terminal alanine could be
identified (Figure 5.15B). This is a well-known behavior of oxidized peptides in CID: the ion
series stops at an oxidized cysteine residue.171 To gain a more informative CID spectrum,
the measurement was repeated with the reduced sample and, as expected, showed a clear
ion series covering almost the full peptide (Figure 5.15D). From the data it was concluded
that C19GADLEC25A was the correct assignment. In general, CID spectra were evaluated for
all disulfide-containing fragments to ascertain the assignments.
A B
C D
Figure 5.15: Detailed analysis of a disulfide-containing fragment by CID. A) mass spectrum of a disulfide-
containing fragment. B) CID fragment spectrum of the same peak. C) Mass spectrum of the same fraction
after reduction with DTT. D) CID fragment spectrum of the reduced fragment.
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Table 5.3: Disulfide-connected fragments identified by mass spectrometry.
full-length tridegin P2 N-terminal part P6
Fragment [M+H]+
expected
[M+H]+
founda
[M+H]
expected
[M+H]+
founda
Connection Isomer
1321.644 1321.628 1321.644 1321.637 C5-C17 A
765.342 – 765.342 765.321 C5-C17 A
1353.670 1353.673 1353.670 1353.659 C5-C31 C
797.368 – 797.368 797.341 C5-C31 C
1544.819 1544.817 – – C5-C37 B
– – 1472.775 1472.812 C5-C37 B
645.217 645.203 645.217 645.204 C17-C31 B
983.412 983.399 983.412 – C17-C31 B
836.366 836.362 – – C17-C37 C
– – 764.322 764.322 C17-C37 C
1206.588 1206.589 – – C31-C37 A
– – 796.351 796.338 C31-C37b A
– – 778.351 778.337 C31-C37b A
779.270 779.270 779.270 – C19-C25 A,B,C
1313.482 1313.480 1313.482 1313.464 C19-C25 A,B,C
a if detected in a higher charged state, [M+H]+ was calculated. b In case of P6, C37 is the amidated C-terminus of the
peptide.
The approach was repeated in a similar manner with the isolated N-terminal region (P6)
of tridegin. Due to a lower complexity of this peptide, the pre-separation of the digest on
HPLC could be omitted and the digest was directly analyzed by LC-ESI MS. The resulting
disulfide-connected fragments for full-length tridegin P2 and the N-terminal variant P6 are
shown in Table 5.3.
In total, three different isomers could be identified in both the oxidized tridegin P2 and
the N-terminal part P6: isomer A with a connectivity of C5-C17, C19-C25 and C31-C37,
isomer B with C5-C37, C17-C31 and C19-C25 and isomer C with C5-C31, C17-C37 and
C19-C25. Remarkably, all three isomers contain the C19-C25 bridge, and, at the same time,
all three possible isomers containing this bridge are present. It is noteworthy that both, P2
and P6, showed the same disulfide connectivities, which indicates that the presence of the
C-terminal part of tridegin does not greatly influence the folding process. Furthermore, the
fact that three different disulfide-connected isomers were formed indicates that the primary
sequence of tridegin does not drive the folding process under the given conditions into a
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single, energy-minimized folded state. This can be either due to the folding conditions
applied (i.e. oxidative self-folding in buffer in the presence of GSSG and GSH, without any
protein disulfide isomerase or chaperones) or it could be an intrinsic property of the peptide.
Whether or not different disulfide-linked isomers of peptides may occur in nature is not yet
fully understood.
However, the presence of small amounts of dimeric tridegin in the synthetic product
(section 5.2.1) could also indicate that the monomeric form is not the most stable or “native”
one, which would explain the presence of different isomers in this case. Elucidation of the
structure of dimeric tridegin might help to answer this question and thus represents an
interesting future task.
5.4.3 Side-product formation during oxidation of disulfide-linked tridegin
analogues
After 24 h of oxidation in buffer, there was still some partially oxidized P6 left, which did
not reach full oxidation even in the presence of air oxygen. This side product had two free
thiol groups, as could be identified by iodoacetamide derivatization and subsequent MS
analysis. To analyze the stable side product further, MS/MS analysis was carried out on the
iodoacetamide-derivatized and subsequently reduced product. CID fragmentation of this
product allowed the localization of the alkylated cysteine residues (Figure 5.16). These were
found to be C19 and C37. Interestingly, C19 is in all of the fully oxidized species part of the
C19-C25 bridge. In case of this by-product, C25 forms a disulfide bridge with C5, C17 or
Figure 5.16: CID fragmentation pattern of alkylated and reduced side product occurring after P6 oxidation.
The b-ion series is indicated by dashed lines, the y-ion series by dotted lines. C* denotes alkylated cysteine
residues. Some unassigned peaks hint on at least one other partly oxidized species present. However, the
assignment given here was the best fit for this spectrum.
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C31, which seems to result in an irreversibly misfolded state in which C19 is not able to form
a bond to the remaining C37.
Incompletely oxidized species have also been found in tridegin P2 after oxidation, but due
to the higher complexity of this peptide, detailed analysis was not accomplished. Nevertheless,
one can assume that a similar misfolding may occur in P2.
5.4.4 Disulfide connectivity of recombinant tridegin
The disulfide connectivity of recombinant tridegin was assessed as well. In this case, a
pre-separation of the digest was not performed, but the digest was directly analyzed by
LC-MS. Evaluation of the data was done in a semi-automated fashion, in which the digest
of all 15 isomers were simulated with Bruker BioTools software and then compared to the
generated data. The automatic evaluation was then manually reviewed and assignments
with >50 ppm mass deviation were removed.
A full sequence coverage could only be shown for isomer B, as well as the two other
possible isomers containing the C5-C37 link. However, the fragments supporting these two
isomers do also fit for isomer B, i.e. they are not unambiguous, while there is one fragment
(C19GADLEC25AQDQY, oxidized) that unambiguously supports isomer B (Table 5.4). Isomers
A and C also give relatively high sequence coverage, but not all disulfide bonds could be
confirmed by peptide fragments. It was therefore concluded that the data only supports the
presence of isomer B.
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Table 5.4: Sequence coverage for all 15 isomers in recombinant tridegin digest. In the overview, gray bars
show an assigned peptide, red boxes indicate confirmation by MS/MS.
% coverage by
Isomer MS MS/MS Overview
C5-C17,C19-
C25,C31-C37 (A)
97.0 78.8
C5-C17,C19-
C31,C31-C37
68.2 50.0
C5-C17,C31-
C37,C25-C31
86.4 68.2
C5-C19,C17-
C25,C31-C37
81.8 63.6
C5-C19,C17-
C31,C25-C37
71.2 53.0
C5-C19,C17-
C37,C25-C31
68.2 50.0
C5-C25,C17-
C19,C31-C37
81.8 63.6
C5-C25,C17-
C31,C19-C37
89.4 72.7
C5-C25,C17-
C37,C19-C31
68.2 50.0
C5-C31,C17-
C19,C25-C37
71.2 65.2
C5-C31,C17-
C25,C19-C37 (C)
89.4 83.3
C5-C31,C17-
C37,C19-C25
86.4 45.5
C5-C37,C17-
C19,C25-C31
100 93.9
C5-C37,C17-
C25,C19-C31
100 93.9
C5-C37,C17-
C31,C19-C25 (B)
100 93.9
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5.5 Molecular Modeling of Tridegin
Molecular modeling of all three isomers of P2 was performed by Dr. A. Biswas (University
Hospital Bonn) using Yasara (Figure 5.17).173 All three isomers show primarily flexible loops,
β-and γ-turns as well as 3-4 helices (between 32 % and 41 % in total). The helix content is
somewhat higher than predicted from former CD spectra (5 %).53 Interestingly, the helices
between residues 5-8, 24-27 and 41-50 are present in all three isomers, which suggests
that these helices form the core structural fold of the peptide (Figure 5.18). Helices have
already been predicted (without prior knowledge of cysteine connectivity) for the residues
6-9 and 47-51 using PSIPRED.53,174 Apart from this similarity, however, the different disulfide
connectivities in the isomers result in three different overall structures, which cannot be
superposed.
Besides the secondary structure of the peptide backbone, the conformation of the disul-
fide bonds is also of major interest. They can be classified according to Schmidt (see
section 2.6).145 Table 5.5 reflects this classification. The C19-C25 disulfide bond that is
present in all three isomers, shows the same +/−LHHook conformation in all the models.
Furthermore, isomers A and B each contain one bridge with a −RHStaple conformation,
which has been described as allosteric disulfide bond conformation that can induce functional
changes in a protein when cleaved or oxidized. They also tend to have a high potential
energy. This might indicate that these disulfide bonds are of importance for the structural
stability of tridegin.
Table 5.5: Configuration of disulfide bonds in computational models of tridegin. The χ-angles were derived
from PDBsum,172 classification was performed according to Schmidt et al.145
Disulfide bridge Configuration χ1 χ2 χ3 χ
′
2 χ
′
1
Isomer A
Cys5 – Cys17 −RHStaple −137.6 −67.4 162.4 −85.2 −156.7
Cys19 – Cys25 +/−LHHook −68.4 −71.6 −164.2 68.6 22.9
Cys31 – Cys37 −/+RHHook 69.8 113.4 97.2 −77.9 −63.1
Isomer B
Cys5 – Cys37 +/−LHSpiral 167.6 −96 −60.3 −177.4 −163.4
Cys17 – Cys31 −RHStaple −160.9 −5.2 163.9 −49.1 −48.1
Cys19 – Cys25 +/−LHHook −46.4 −48.7 −144.7 74.3 61.7
Isomer C
Cys5 – Cys31 −RHHook −74.2 −92.7 137.8 40.1 −176
Cys17 – Cys37 −/+LHHook 23.1 109.7 −82.5 −32 −55.8
Cys19 – Cys25 +/−LHHook 67.8 −139.9 −103.4 73.3 −83.6
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Figure 5.17: Computational models of the three tridegin isomers (left, by YASARA) and schematic topology
(right, by PDBsum172). The structures are colored according to secondary structure: α-helix (blue), turns
and coils (cyan), 310-helix (yellow) and pi-helix (green). Disulfide bonds are highlighted in red.
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Figure 5.18: Comparison of secondary structures of the three different tridegin isomers (generated by
PDBsum172).
5.5.1 Comparison with other peptides and proteins
There are two major groups of cysteine connectivities described for leech-derived anti-
coagulants. One of them is the antistasin-type, which contains among others Antistasin,
Hirustasin and Guamerin as well as Ghilanten that is also derived from H. ghilianii. These
peptides/miniproteins contain 5 disulfide bonds which are connected 1-3, 2-4,5-8,6-9 and
7-10.175 The other one is the so-called leech antihemostatic protein (LAP) motif, which
includes Decorsin, Hirudin, Haemadin and Ornatin. These peptides contain six cysteine
residues with a disulfide pattern 1-2,3-5 and 4-6.176,177 Although the number of cysteine
residues and even their spacing in tridegin is similar to the LAP representatives (see also
Figure 2.8), tridegin clearly shows a different disulfide connectivity. This also results in a
different secondary structure: for Hirudin, Decorsin and Haemadin crystal- and/or NMR
structures are available, and none of them shows α-helices in their secondary structure (e.g.
PDB entries 1HIC,165 2PW8,178 1DEC,179 1E0F177).
5.6 Structure-Activity-Relationship
5.6.1 General relationships of the tridegin-FXIIIa-interaction
The interaction of tridegin with FXIIIa is rather complex. Simply removing parts of the
structure changes the way of interaction extensively. It has been shown that some amino
acids in the C-terminal region, such as Ile50, Gln52 and Leu62 are important for potency
of the inhibitor.151 In general, the C-terminal part shows inhibition of FXIIIa, however, this
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inhibition is more precisely described as substrate competition. Addition of all N-terminal
amino acids does not increase inhibitor potency much, but prevents the substrate-like behavior
of the inhibitor in the presence of FXIIIa. In contrast, oxidation of the 6 cysteine residues in
the N-terminus is not necessary for preventing the substrate-like behavior, but does increase
inhibitor potency. The isolated N-terminal part, however, independently of being oxidized or
not, does not inhibit FXIIIa. This already indicates a contribution to inhibitor binding, but not
direct interaction of the N-terminal region of tridegin with the active site of FXIIIa. Binding
studies support this hypothesis and could show that the isolated, oxidized N-terminal part
does efficiently bind to FXIIIa, possibly to a binding site in some distance to the active center
of the enzyme. Up to now, no experimental data is available on which of the three different
isomers present in the monomeric tridegin preparation shows the highest affinity or inhibitor
potency to FXIIIa. However, the high potency of the dimeric tridegin suggests that this might
be the biologically relevant form.
With this information in mind, docking studies of the three monomeric isomers to FXIII-A°
were performed and evaluated.
5.6.2 Docking of tridegin to FXIII-A°
The new crystal structure of activated FXIII-A° was used for docking experiments with the
three modeled isomers of tridegin. Docking was performed by A. Biswas (University Hospital
Bonn) who kindly provided the docking data.
First, the general docking regions of the three different isomers were analyzed. While
isomers A and B bind to a region close to the active site, the best dock for isomer C is in a
completely different part of the FXIII-A° structure and does not interact directly with atoms
of FXIII-A°. Figure 5.19 gives a superposition of the docking sites for all three isomers.
In general, isomers A and B showed a number of putative interactions with residues in
or close to the active site of FXIII-A°, while isomer C did not show any interactions even
in the best fitted docks. Therefore, mainly isomer A and B will be discussed. The putative
interactions of these two isomers with the FXIII-A° structure are listed in Table 5.6. Some
of these interactions are also indicated in Figure 5.20. From these data it becomes clear
that the two different isomers A and B bind in completely different ways to the active site
of FXIII-A°. Isomer A binds predominantly with the N-terminal part to FXIII-A° and shows
direct interactions between the active site cysteine (Cys314) in FXIII-A° and Gln10 in tridegin.
This is surprising, because Gln10 has not yet been associated with inhibitory potency of
tridegin, however a targeted mutation of this site has never been evaluated. Interestingly,
the N-terminal region of isomer A penetrates the substrate tunnel of FXIII-A° in a way that
the peptide chain enters through the side of the tunnel that is assumed to normally allow
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Figure 5.19: Docking of the three different tridegin isomers to the FXIII-A° structure. Isomer A is shown in
red, B in green and C in blue. The localization of the active site is indicated with a yellow circle.
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A B
C D
Figure 5.20: Details and interactions of the docking region for A) isomer A and B) isomer B. The backbone
of FXIII° is shown in green, tridegin in blue. Active site residues are indicated in yellow and Gln10 and Gln52
in red. The surface representation (C and D) of FXIII° shows the tunnel for entrance of the amine substrate
(arrow) and the relative localization of isomer A and B, respectively.
entrance of the amine substrate (Figure 5.20). This would effectively inhibit the enzyme.
Whether or not this mode of binding contributes to inhibitory action of tridegin remains
questionable, as long as no experimental proof is found. In any case, this type of binding
is completely different to what has been observed for isolated C-terminal parts of tridegin,
where Gln52 clearly interacts with the active site of FXIIIa and Gln10 is not even present.
Most interactions of isomer B with FXIII-A°, in contrast, are located in the C-terminal
part of the peptide. In this case, Gln52 is located relatively close to the active site cysteine
residue (12 Å), but too far away for direct interaction. Still, given the inaccuracy generated
by the modeling and the docking step, this binding mode might explain the effects seen in
C-terminal peptides of tridegin. In contrast to isomer A, isomer B does not penetrate the
tunnel near the active site of the enzyme, but probably blocks access from the entrance site
for the glutamine containing substrate. This type of binding would therefore also be expected
to inhibit FXIII-A°.
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Table 5.6: List of putative interactions of the tridegin isomers A and B with FXIII-A°. The atoms taking part in
the putative interaction are given in square brackets and follow the PDB nomenclature.180
Isomer A Isomer B
Tridegin Dist. [Å] FXIIIA° Tridegin Dist. [Å] FXIIIA°
Hydrogen bonds Hydrogen bonds
Asn14 [N] 2.90 Ser368 [OG] Lys1 [NZ] 3.3 Glu216 [OE1]
Glu7 [O] 3.72 Trp279 [NE1] Tyr51 [OH] 2.10 Gly215 [O]
Gln10 [O] 3.29 His373 [ND1] Arg53 [NH2] 3.26 Asn281 [OD1]
Gln10 [OE1] 3.21 Cys314 [SG] Val55 [N] 3.51 Gln313 [OE1]
Gln10 [OE1] 3.32 Cys314 [N] Lys63 [NZ] 2.56 Asp456 [OD2]
Gln10 [OE1] 3.39 Trp315 [N] Tyr51 [O] 2.96 Arg223 [NH2]
Pro13 [O] 3.76 Val369 [N] Tyr51 [O] 3.86 Tyr372 [OH]
Ser41 [O] 2.24 Val360 [N] Tyr51 [OH] 3.70 Glu216 [N]
Ser41 [OG] 3.43 Val360 [N] Asn59 [O] 3.01 Val369 [N]
Ser41 [OG] 3.45 Asn361 [N] Pro61 [O] 3.59 His459 [NE2]
Asp48 [OD2] 3.33 Tyr441 [OH]
Salt bridges Salt bridges
Asp48 [OD1] 3.90 His459 [NE2] Lys1 [NZ] 3.33 Glu216 [OE1]
Lys63 [NZ] 2.56 Asp456 [OD2]
In general it is encouraging that two out of three isomers readily fit into the active site
of FXIII° in a way that would inhibit the enzyme. The orientation of isomer A is surprising
and generates a new hypothesis that would be worthwhile to be tested by e.g. synthesizing
a Gln10Ala mutant. The discrepancy between experimental findings for the reaction of
Gln52 with the active site of FXIIIa and the docking of isomer A might also explain in parts
the different binding modes suggested for N-terminally truncated and full-length tridegin.
However, this binding mode would nicely explain the high affinity of the isolated N-terminal
part of tridegin to FXIIIa. The binding of isomer B relates more closely to the experimental
findings for the importance of Gln52, although a direct interaction with the active site was
not demonstrated. On the other hand, this model fails to explain the affinity of the N-terminal
region of tridegin to FXIIIa, as most interactions are located in the C-terminal part of the
inhibitor. Isomer C did not interact with FXIII-A° in the present docking study, which, however,
does not need to be true in reality.
For further studies, experimental confirmation of the models and docking studies would be
of high interest. The targeted synthesis of all three isomers via solid-phase peptide synthesis
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and orthogonal protecting group strategies is challenging, but a successful preparation of
the single isomers would allow individual structural and functional studies which would in
turn refine the findings presented here.
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Factor XIIIa (FXIIIa), a transglutaminase catalyzing the covalent cross-linking of fibrin in the
final step of blood coagulation, is an interesting pharmaceutical target due to its multiple
functions and involvement in a number of pathophysiological processes. Moreover, there
is still a lot of research ongoing to further elucidate the role of this enzyme in- and outside
of cells. Therefore, there is a need for specific, effective and well-characterized inhibitors
for FXIIIa. The only natural peptidic FXIIIa inhibitor available so far, tridegin, has been
isolated from the giant amazon leech Hamenteria ghilianii in 1997. The detailed structural
and functional characterization of this 66mer peptide was the aim of this thesis.
Synthesis First, the inhibitor was synthesized according to a protocol already established
in the laboratory. Different full-length variants of the peptide (synthetic, recombinant,
monomeric, dimeric) were prepared as well as a series of N-terminally truncated peptides.
Additionally, the peptide sequence was separated into a 37-mer N-terminal part and a 29-mer
C-terminal part, both of which were synthesized. An overview of the synthesized linear
precursors is given in Figure 6.1.
The isolated N-terminal part as well as the full-length peptide were allowed to self-
fold and form disulfide bonds, which is a way to prepare disulfide-bonded peptides with
unknown native disulfide connectivity. From peptides P1, P2, P6 and P7 fluorescence-
labeled derivatives were prepared by N-terminal coupling of carboxyfluoresceine, resulting
in peptides P15, P16, P17 and P18, respectively.
Figure 6.1: Overview over all synthesized linear precursors. Peptide P1 was oxidized to a monomeric (P2)
and a dimeric (P3) form. Peptide P6 was prepared only in an oxidized version. Peptides with indicated amino
acids contain mutations of the original sequence at the given positions.
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In an orthogonal approach, tridegin was also expressed recombinantly in E. coli. Expression
of the peptide was reproduced and optimized from a formerly published protocol using an
artificial DNA, since the original cDNA sequence encoding tridegin is not known.
Functional assays The different tridegin variants were subjected to functional analyses.
The inhibitory potency of the compounds was analyzed by enzyme activity assays. It was
shown that the C-terminal part P7 did inhibit FXIIIa with only about 4fold higher IC50 values
than those measured for oxidized full-length tridegin P2 (2.2µM and 0.5µM, respectively).
In contrast, the N-terminal part P6 did not inhibit FXIIIa at all. Furthermore, the linear variant
of tridegin showed an IC50 of 1.5µM, which strengthens the assumption that the disulfide
connectivity plays an important role in inhibitor function. This was further confirmed by
assaying a mutant peptide containing only serine residues instead of cysteine (P5) which
resulted in a similar potency (IC50 2.1µM). Therefore it was concluded, that the presence
of the N-terminal part only increases inhibitor potency when disulfide bonds are formed.
However, an interesting finding remains: while the isolated C-terminal part P7 loses its
inhibitory function over time in presence of FXIIIa (i.e. is a competing substrate of the
enzyme, in which Gln52 is turned into Glu), this behavior could not be observed with any of
the full-length derivatives, oxidized or not. This either means that the full-length variants
are not substrates of FXIIIa or that the product of this hypothetic reaction (i.e. the Glu52
mutant) still inhibits FXIIIa.
Furthermore, the recombinantly expressed peptide P4 was analyzed, but showed a lower
potency (IC50 of 1.2µM) than the synthesized, oxidized peptide. In contrast, a synthetic,
covalent dimer (P3) displayed am IC50 value of 0.1µM. This leads to the assumption that
the dimeric form might be the native one.
In general, the inhibition of FXIIIa by tridegin seems to be very complex and cannot be
described by e.g. a simple competitive mechanism. Also, the analyses performed did indicate
a 1:2 stoichiometry between FXIIIa and tridegin.
To further assess the function of the non-inhibitory N-terminal part, binding assays were
performed. In a thermophoresis experiment, the fluorescence-labeled peptides were incu-
bated with different forms of FXIII and binding was monitored. These experiments revealed
that linear and oxidized tridegin as well as the isolated N- and C-terminal parts did bind
to FXIIIa, but none of the peptides bound to non-activated FXIII (A-subunit) or the carrier
B-subunit. A potential explanation for the impact of the N-terminal part on inhibitor potency
is that it enhances binding of the inhibitor to the enzyme, potentially by association with a
secondary binding site different from the active center.
The structure-activity relationships gained from these experiments are summarized in
Figure 6.2.
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Figure 6.2: Structure-Activity-Relationships in tridegin (isomer B). Disulfide bonds are indicated in red, the
N-terminal part of the peptide (1-37) is colored blue, the C-terminal part (38-66) orange. The important Gln52
position is highlighted in green.
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Structure elucidation For a detailed understanding of the tridegin structure, elucidation
of the disulfide connectivity is of major importance. No suitable homologue for directly
inferring disulfide connectivity could be found, therefore the disulfide bonds had to be
determined de novo from both the synthetic and recombinant material. Crystallization of
tridegin in presence and absence of factor XIII was attempted in cooperation with Dr. M.
Than (FLI Jena) but was not successful. Thus, the oxidized peptides – full length tridegin
synthetic (P2) and recombinant (P4) as well as the isolated N-terminal analogue P6 – were
subjected to enzymatic digestion and subsequent mass spectrometric analysis. This method
was successful, and three different isomers could be identified in both P2 and P6. One of
them could also be confirmed in recombinant tridegin.
This information was then used to perform molecular modeling of the structures (in
cooperation with Dr. A. Biswas, University Hospital Bonn) and docking of the modeled
tridegin isomers to the structure of active FXIII. Two of the three identified isomers were
shown to dock to the active site of FXIIIa in silico exhibiting different binding modes.
Outlook In summary, this work greatly enhances the understanding of the FXIIIa inhibitor
tridegin. Further experimental studies are needed to assess the inhibitor potency and binding
of the three different isomers individually. Also, evaluation of full-length variants with single
amino acid mutations based on the docking experiments would be useful to confirm the
in silico studies and pinpoint interaction sites between FXIIIa and tridegin. Subsequently,
further optimization of the inhibitor might be possible.
Although some questions still remain, tridegin is now one of the best-characterized in-
hibitors for FXIIIa and might therefore serve both as research tool for the investigation of
FXIIIa function in vitro and in vivo, as well as a lead structure for FXIIIa inhibitor development.
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Abbreviations of amino acids and their derivatives are used acoording to the recommendation
of the Nomenclature Committee of IUB (NC-IUB) and the IUPAC-IUB Joint Commission on
Biochemical Nomenclature (JCBN).181 If not stated otherwise, amino acids and amino acid
derivatives are L-configured.
α2AP α2-Antiplasmin
5-FAM 5-Carboxyfluorescein
Abz 2-Aminobenzoic acid
APCE Antiplasmin cleaving enzyme
APS Ammonium persulfate
bp base pairs
CD Circular dichroism
cFXIII Cellular factor XIII
CID Collision induced dissociation
CMK Chloro methyl ketone
DCM Dichlormethane
DIEA N,N-Diisopropylethylamine
DMF N,N-Dimehtylformamide
DTT Dithiothreitol
DVT Deep vein thrombosis
EDTA Ethylenediaminetetraacetic acid
eq. Equivalents
ESI Electro spray ionization
EST Expressed sequence tag
Fmoc Fluorenylmethyloxycarbonyl protecting group
FRET Förster resonance energy transfer
FXIII Factor XIII
FXIIIa Activated factor XIII
GSH Glutathione (reduced)
GSSG Glutathione (oxidized)
H-Gly-OEt Glycine ethyl ester
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Abbreviations
HBTU O-benzotriazol-N,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate
HPLC High performance liquid chromatography
IAA Iodoacetamide
IC50 Half maximal inhibitory concentration
IPTG Isopropyl β-D-1-thiogalactopyranoside
LC Liquid chromatography
MALDI Matrix assisted laser desorption/ionization
MAP Michael acceptor pharmacophore
MASP1 Mannan-binding lectin-associated serine protease-1
MS Mass spectrometry
NMR Nuclear magnetic resonance
PAGE Polyacrylamide gel electrophoresis
PAI-2 Plasminogen activator inhibitor 2
PCR Polymerase chain reaction
pFXIII Plasma factor XIII
PyBOP Benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate
SDS Sodium dodecyl sulfate
SPPS Solid phase peptide synthesis
t-PA Tissue-type plasminogen activator
TAFI Thrombin activatable fibrinolysis inhibitor
TAFIa Thrombin activatable fibrinolysis inhibitor (activated)
TEMED N,N,N’,N’-Tetramethylethane-1,2-diamine
TFA Triflouroacetic acid
Tgase Transglutaminase
TLC Thin layer chromatography
TOF Time of flight
Tris Tris(hydroxymethyl)aminomethane
u-PA Urokinase-type plasminogen activator
VTE Venous thromboembolism
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